Another Question

[Guest guest]

They are when you compare geno 1' s with everything the same BUT when you compare overweight geno1's,, Sherring's Peg-Intron has better odds.. I wish I could find the article that said that,, I know I have it somewhere.. the ONLY ones where there IS a significant improved risk to make SVR was with OVERWEIGHT geno 1''s..elizabethnv1 <elizabethnv1@...> wrote: To be honest the stats are pretty much the same when it comes to peg or pegasys , but if you used something like Infergen it has

higher success rates . Re: Re: Another Question I have a question, too, one that I've never really had answered, or else I didn't understand. As of right now, which drug company has had the

better results with obtaining remission in Genotype "1"s, Schering-Plough or Roche? I am still struggling along here.. right along, I'm sure with a few others... Thanks in Advance, Sheena <marvindamartian05 > wrote: hat does SAE stand for? -- In Hepatitis C , "elizabethnv1"<elizabethnv1@...> wrote:>> PegIntron/RBV Effective for >65 Year Olds> > Reported by

Jules Levin> AASLD, Oct 27-31, 2006, Boston, MA> > “Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > and Well Tolerated in Patients >65 Years Old in Comparison to Other > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R > Trial)â€> > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. Pound,10 J. > Harvey,11 L. H. Griffel,11 C. A. Brass11> 1Northwestern University, Chicago, Illinois; 2Weill Medical College > of Cornell University, New York, New York; 3Columbia University > College of Medicine, New York, New York; 4Baptist Medical Center, > Kansas City, Missouri;> 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > 6Indiana University School of Medicine, Indianapolis, Indiana; > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;

8Austin > Gastroenterology, PA, Austin, Texas;> 9California Pacific Medical Center, San Francisco, California; > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > AUTHOR CONCLUSIONS> Patients 18 to 25 years of age had the highest SVR rate (57%) among > the 6 age groups.> > The SVR rate in patients older than 65 years (46%) was similar to the > SVR rates observed in younger age groups (41%-57%).> > Although elderly patients tended to experience more AEs, the rate of > SAEs was similar in all groups, and the incidence of treatment > discontinuation in elderly patients was similar to or less than that > of younger patients.> > Data from this subanalysis of the WIN-R trial strongly suggest that > patients should not be denied antiviral therapy based on age

alone.> > > Abstract*> Background: Peg interferon (IFN) + ribavirin are the standard of care > for chronic HCV. There is reluctance to administer anti-viral > medications to older populations due to a fear of side effects and > possible decreased efficacy. Limited data is available on pts. age > >65 due to ineligibility for clinical trials. The role of age in > determining response to IFN-based antiviral therapy for chronic HCV > has not been clearly defined.> > Aim: To determine if age is an independent predictor of sustained > virological response (SVR) or medication tolerability within a > randomized, controlled clinical trial of treatment-naive pts. with > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > yrs., n=55.> > Methods: A retrospective

review of the multi-center WIN-R trial > database was undertaken. Pts. were randomized to receive PEG IFN 2b > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of therapy > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of therapy. > 4913 pts. received at least 1 dose of medication and are included in > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > pts. Were enrolled as protocol exceptions. Logistic regression > analyses of SVR comparing two age categories were performed. The > potential influence of demographic variables on SVR was evaluated > using the chi square test (two-way frequency table).> > Results: > The overall SVR was 44%. > > SVR rates for the grps were: > 18-25 yrs. = 57%, > 26-35 yrs. = 41% (p=0.02 vs 18-25),> 36-45 yrs.

= 44% (p=0.03 vs 18-25), > 46-55 yrs. = 42%, > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > >65 yrs. SVR = 45%.> > There was no difference in SVR in any other pt. age grps including > pts. age >65 yrs. > > There were no differences in SAEs between all age groups. Pts. age 26-> 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in the 56-> 65 yrs. and the >65 yrs. age groups. > > Treatment discontinuations were significantly higher among the 26-35 > yrs. group when compared to two groups but there was no difference in > the treatment discontinuations in the >65 yrs. group compared with > any other.> > Conclusions: > 1) Adults age 18-25 yrs. had significantly increased chances of > obtaining SVR than most other age groups.> 2) Pts. >65 had similar SVR to all other age groups. > 3) Although there were more

AEs in the older age groups, the rate of > SAEs was the same and treatment drop-outs were the same or less than > the younger age groups. > 4) Pts. should not be denied anti-viral therapy based upon age alone.> > *Poster presents data updated since abstract submission.> > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> R) study was a prospective, multicenter, community and academic-> based, open-label, investigator-initiated, US clinical trial that > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > or weight-based ribavirin in treatment-naive patients with chronic > hepatitis C.> - Overall SVR rates were 44% in the weight-based ribavirin arm and > 41% in the flat-dose ribavirin arm (P = .020).3> - SVR rates in patients with chronic hepatitis C caused by hepatitis > C virus (HCV) genotype 1 (G1) were 34% and

29%, respectively (P > =.004).3> - Weight-based ribavirin dosing was associated with higher rates of > dose reduction for anemia but not with higher rates of > discontinuation.3> Everyone is raving about the all-new beta. Jackie

[Guest guest]

Hey, there is something called Virazole, which it says is an inhalant

version of Ribavarin. anyone have any experience with this?

> > >

> > > PegIntron/RBV Effective for >65 Year Olds

> > >

> > > Reported by Jules Levin

> > > AASLD, Oct 27-31, 2006, Boston, MA

> > >

> > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally

> Efficacious

> > > and Well Tolerated in Patients >65 Years Old in Comparison to

> Other

> > > Age Groups: Subanalysis of a Randomized, Controlled Study

> (WIN-R

> > > Trial)â?

> > >

> > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N.

> > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> Pound,10 J.

> > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > 1Northwestern University, Chicago, Illinois; 2Weill Medical

> College

> > > of Cornell University, New York, New York; 3Columbia

> University

> > > College of Medicine, New York, New York; 4Baptist Medical

> Center,

> > > Kansas City, Missouri;

> > > 5Beth Israel Deaconness Medical Center, Boston,

> Massachusetts;

> > > 6Indiana University School of Medicine, Indianapolis,

> Indiana;

> > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;

> 8Austin

> > > Gastroenterology, PA, Austin, Texas;

> > > 9California Pacific Medical Center, San Francisco,

> California;

> > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana;

> > > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> > >

> > > AUTHOR CONCLUSIONS

> > > Patients 18 to 25 years of age had the highest SVR rate (57%)

> among

> > > the 6 age groups.

> > >

> > > The SVR rate in patients older than 65 years (46%) was

> similar to the

> > > SVR rates observed in younger age groups (41%-57%).

> > >

> > > Although elderly patients tended to experience more AEs, the

> rate of

> > > SAEs was similar in all groups, and the incidence of

> treatment

> > > discontinuation in elderly patients was similar to or less

> than that

> > > of younger patients.

> > >

> > > Data from this subanalysis of the WIN-R trial strongly

> suggest that

> > > patients should not be denied antiviral therapy based on age

> alone.

> > >

> > >

> > > Abstract*

> > > Background: Peg interferon (IFN) + ribavirin are the standard

> of care

> > > for chronic HCV. There is reluctance to administer anti-viral

> > > medications to older populations due to a fear of side

> effects and

> > > possible decreased efficacy. Limited data is available on

> pts. age

> > > >65 due to ineligibility for clinical trials. The role of age

> in

> > > determining response to IFN-based antiviral therapy for

> chronic HCV

> > > has not been clearly defined.

> > >

> > > Aim: To determine if age is an independent predictor of

> sustained

> > > virological response (SVR) or medication tolerability within

> a

> > > randomized, controlled clinical trial of treatment-naive pts.

> with

> > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs.,

> n=350;

> > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

> and >65

> > > yrs., n=55.

> > >

> > > Methods: A retrospective review of the multi-center WIN-R

> trial

> > > database was undertaken. Pts. were randomized to receive PEG

> IFN 2b

> > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-

> 1400

> > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of

> therapy

> > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of

> therapy.

> > > 4913 pts. received at least 1 dose of medication and are

> included in

> > > this analysis. Although pts. age >65 yrs. were ineligible, 55

> such

> > > pts. Were enrolled as protocol exceptions. Logistic

> regression

> > > analyses of SVR comparing two age categories were performed.

> The

> > > potential influence of demographic variables on SVR was

> evaluated

> > > using the chi square test (two-way frequency table).

> > >

> > > Results:

> > > The overall SVR was 44%.

> > >

> > > SVR rates for the grps were:

> > > 18-25 yrs. = 57%,

> > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > 46-55 yrs. = 42%,

> > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for

> > > >65 yrs. SVR = 45%.

> > >

> > > There was no difference in SVR in any other pt. age grps

> including

> > > pts. age >65 yrs.

> > >

> > > There were no differences in SAEs between all age groups.

> Pts. age 26-

> > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those

> in the 56-

> > > 65 yrs. and the >65 yrs. age groups.

> > >

> > > Treatment discontinuations were significantly higher among

> the 26-35

> > > yrs. group when compared to two groups but there was no

> difference in

> > > the treatment discontinuations in the >65 yrs. group compared

> with

> > > any other.

> > >

> > > Conclusions:

> > > 1) Adults age 18-25 yrs. had significantly increased chances

> of

> > > obtaining SVR than most other age groups.

> > > 2) Pts. >65 had similar SVR to all other age groups.

> > > 3) Although there were more AEs in the older age groups, the

> rate of

> > > SAEs was the same and treatment drop-outs were the same or

> less than

> > > the younger age groups.

> > > 4) Pts. should not be denied anti-viral therapy based upon

> age alone.

> > >

> > > *Poster presents data updated since abstract submission.

> > >

> > >

> > > The Weight-Based Dosing of Peginterferon alfa-2b and

> Ribavirin (WIN-

> > > R) study was a prospective, multicenter, community and

> academic-

> > > based, open-label, investigator-initiated, US clinical trial

> that

> > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

> flat-dose

> > > or weight-based ribavirin in treatment-naive patients with

> chronic

> > > hepatitis C.

> > > - Overall SVR rates were 44% in the weight-based ribavirin

> arm and

> > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > - SVR rates in patients with chronic hepatitis C caused by

> hepatitis

> > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively

> (P

> > > =.004).3

> > > - Weight-based ribavirin dosing was associated with higher

> rates of

> > > dose reduction for anemia but not with higher rates of

> > > discontinuation.3

> > >

> >

> >

> >

> >

> >

> >

> > ----------------------------------------------------------

> ----------

> > Everyone is raving about the all-new beta.

> >

>

>

>

>

>

>

> ---------------------------------

> Everyone is raving about the all-new beta.

>

[Guest guest]

Please define " overweight " . I am serious here really....I am about 20

lbs overweight right now (based on how I consider that I look my best)

but if you go by BMI, I am about 30 lbs overweight. Does overweight

mean, 5 lbs, 10 lbs, 50 lbs....?

> >

> > PegIntron/RBV Effective for >65 Year Olds

> >

> > Reported by Jules Levin

> > AASLD, Oct 27-31, 2006, Boston, MA

> >

> > “Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious

> > and Well Tolerated in Patients >65 Years Old in Comparison to Other

> > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R

> > Trial)â€

> >

> > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N.

> > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. Pound,10 J.

> > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > 1Northwestern University, Chicago, Illinois; 2Weill Medical College

> > of Cornell University, New York, New York; 3Columbia University

> > College of Medicine, New York, New York; 4Baptist Medical Center,

> > Kansas City, Missouri;

> > 5Beth Israel Deaconness Medical Center, Boston, Massachusetts;

> > 6Indiana University School of Medicine, Indianapolis, Indiana;

> > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; 8Austin

> > Gastroenterology, PA, Austin, Texas;

> > 9California Pacific Medical Center, San Francisco, California;

> > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana;

> > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> >

> > AUTHOR CONCLUSIONS

> > Patients 18 to 25 years of age had the highest SVR rate (57%) among

> > the 6 age groups.

> >

> > The SVR rate in patients older than 65 years (46%) was similar to the

> > SVR rates observed in younger age groups (41%-57%).

> >

> > Although elderly patients tended to experience more AEs, the rate of

> > SAEs was similar in all groups, and the incidence of treatment

> > discontinuation in elderly patients was similar to or less than that

> > of younger patients.

> >

> > Data from this subanalysis of the WIN-R trial strongly suggest that

> > patients should not be denied antiviral therapy based on age alone.

> >

> >

> > Abstract*

> > Background: Peg interferon (IFN) + ribavirin are the standard of care

> > for chronic HCV. There is reluctance to administer anti-viral

> > medications to older populations due to a fear of side effects and

> > possible decreased efficacy. Limited data is available on pts. age

> > >65 due to ineligibility for clinical trials. The role of age in

> > determining response to IFN-based antiviral therapy for chronic HCV

> > has not been clearly defined.

> >

> > Aim: To determine if age is an independent predictor of sustained

> > virological response (SVR) or medication tolerability within a

> > randomized, controlled clinical trial of treatment-naive pts. with

> > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350;

> > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65

> > yrs., n=55.

> >

> > Methods: A retrospective review of the multi-center WIN-R trial

> > database was undertaken. Pts. were randomized to receive PEG IFN 2b

> > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400

> > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of therapy

> > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of therapy.

> > 4913 pts. received at least 1 dose of medication and are included in

> > this analysis. Although pts. age >65 yrs. were ineligible, 55 such

> > pts. Were enrolled as protocol exceptions. Logistic regression

> > analyses of SVR comparing two age categories were performed. The

> > potential influence of demographic variables on SVR was evaluated

> > using the chi square test (two-way frequency table).

> >

> > Results:

> > The overall SVR was 44%.

> >

> > SVR rates for the grps were:

> > 18-25 yrs. = 57%,

> > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > 46-55 yrs. = 42%,

> > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for

> > >65 yrs. SVR = 45%.

> >

> > There was no difference in SVR in any other pt. age grps including

> > pts. age >65 yrs.

> >

> > There were no differences in SAEs between all age groups. Pts. age 26-

> > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in the 56-

> > 65 yrs. and the >65 yrs. age groups.

> >

> > Treatment discontinuations were significantly higher among the 26-35

> > yrs. group when compared to two groups but there was no difference in

> > the treatment discontinuations in the >65 yrs. group compared with

> > any other.

> >

> > Conclusions:

> > 1) Adults age 18-25 yrs. had significantly increased chances of

> > obtaining SVR than most other age groups.

> > 2) Pts. >65 had similar SVR to all other age groups.

> > 3) Although there were more AEs in the older age groups, the rate of

> > SAEs was the same and treatment drop-outs were the same or less than

> > the younger age groups.

> > 4) Pts. should not be denied anti-viral therapy based upon age alone.

> >

> > *Poster presents data updated since abstract submission.

> >

> >

> > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-

> > R) study was a prospective, multicenter, community and academic-

> > based, open-label, investigator-initiated, US clinical trial that

> > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose

> > or weight-based ribavirin in treatment-naive patients with chronic

> > hepatitis C.

> > - Overall SVR rates were 44% in the weight-based ribavirin arm and

> > 41% in the flat-dose ribavirin arm (P = .020).3

> > - SVR rates in patients with chronic hepatitis C caused by hepatitis

> > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P

> > =.004).3

> > - Weight-based ribavirin dosing was associated with higher rates of

> > dose reduction for anemia but not with higher rates of

> > discontinuation.3

> >

>

>

>

>

>

> ---------------------------------

> Everyone is raving about the all-new beta.

>

>

>

>

>

>

> Jackie

>

[Guest guest]

Never heard of it! Liz??? <marvindamartian05@...> wrote: Hey, there is something called Virazole, which it says is an inhalantversion of Ribavarin. anyone have any experience with this?> > >> > > PegIntron/RBV Effective for >65 Year Olds> > > > > > Reported by Jules Levin> > > AASLD, Oct 27-31, 2006, Boston, MA> > > > > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally > Efficacious > > > and Well Tolerated in Patients >65 Years Old in Comparison to > Other > > > Age Groups: Subanalysis of a Randomized, Controlled Study > (WIN-R > > > Trial)â?> > > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. > Pound,10 J. > > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > > 1Northwestern University, Chicago, Illinois; 2Weill Medical > College > > > of Cornell University, New

York, New York; 3Columbia > University > > > College of Medicine, New York, New York; 4Baptist Medical > Center, > > > Kansas City, Missouri;> > > 5Beth Israel Deaconness Medical Center, Boston, > Massachusetts; > > > 6Indiana University School of Medicine, Indianapolis, > Indiana; > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; > 8Austin > > > Gastroenterology, PA, Austin, Texas;> > > 9California Pacific Medical Center, San Francisco, > California; > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > > > AUTHOR CONCLUSIONS> > > Patients 18 to 25 years of age had the highest SVR rate (57%) > among > > > the 6 age groups.> > > > >

> The SVR rate in patients older than 65 years (46%) was > similar to the > > > SVR rates observed in younger age groups (41%-57%).> > > > > > Although elderly patients tended to experience more AEs, the > rate of > > > SAEs was similar in all groups, and the incidence of > treatment > > > discontinuation in elderly patients was similar to or less > than that > > > of younger patients.> > > > > > Data from this subanalysis of the WIN-R trial strongly > suggest that > > > patients should not be denied antiviral therapy based on age > alone.> > > > > > > > > Abstract*> > > Background: Peg interferon (IFN) + ribavirin are the standard > of care > > > for chronic HCV. There is reluctance to administer anti-viral > > > medications to

older populations due to a fear of side > effects and > > > possible decreased efficacy. Limited data is available on > pts. age > > > >65 due to ineligibility for clinical trials. The role of age > in > > > determining response to IFN-based antiviral therapy for > chronic HCV > > > has not been clearly defined.> > > > > > Aim: To determine if age is an independent predictor of > sustained > > > virological response (SVR) or medication tolerability within > a > > > randomized, controlled clinical trial of treatment-naive pts. > with > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., > n=350; > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; > and >65 > > > yrs., n=55.> > > > > > Methods: A retrospective

review of the multi-center WIN-R > trial > > > database was undertaken. Pts. were randomized to receive PEG > IFN 2b > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-> 1400 > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of > therapy > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of > therapy. > > > 4913 pts. received at least 1 dose of medication and are > included in > > > this analysis. Although pts. age >65 yrs. were ineligible, 55 > such > > > pts. Were enrolled as protocol exceptions. Logistic > regression > > > analyses of SVR comparing two age categories were performed. > The > > > potential influence of demographic variables on SVR was > evaluated > > > using the chi square test (two-way frequency table).>

> > > > > Results: > > > The overall SVR was 44%. > > > > > > SVR rates for the grps were: > > > 18-25 yrs. = 57%, > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > > 46-55 yrs. = 42%, > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > > > >65 yrs. SVR = 45%.> > > > > > There was no difference in SVR in any other pt. age grps > including > > > pts. age >65 yrs. > > > > > > There were no differences in SAEs between all age groups. > Pts. age 26-> > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those > in the 56-> > > 65 yrs. and the >65 yrs. age groups. > > > > > > Treatment discontinuations were significantly higher among > the 26-35 >

> > yrs. group when compared to two groups but there was no > difference in > > > the treatment discontinuations in the >65 yrs. group compared > with > > > any other.> > > > > > Conclusions: > > > 1) Adults age 18-25 yrs. had significantly increased chances > of > > > obtaining SVR than most other age groups.> > > 2) Pts. >65 had similar SVR to all other age groups. > > > 3) Although there were more AEs in the older age groups, the > rate of > > > SAEs was the same and treatment drop-outs were the same or > less than > > > the younger age groups. > > > 4) Pts. should not be denied anti-viral therapy based upon > age alone.> > > > > > *Poster presents data updated since abstract submission.> > > > > > > > > The

Weight-Based Dosing of Peginterferon alfa-2b and > Ribavirin (WIN-> > > R) study was a prospective, multicenter, community and > academic-> > > based, open-label, investigator-initiated, US clinical trial > that > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus > flat-dose > > > or weight-based ribavirin in treatment-naive patients with > chronic > > > hepatitis C.> > > - Overall SVR rates were 44% in the weight-based ribavirin > arm and > > > 41% in the flat-dose ribavirin arm (P = .020).3> > > - SVR rates in patients with chronic hepatitis C caused by > hepatitis > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively > (P > > > =.004).3> > > - Weight-based ribavirin dosing was associated with higher > rates of > > > dose

reduction for anemia but not with higher rates of > > > discontinuation.3> > >> > > > > > > > > > > > > > ----------------------------------------------------------> ----------> > Everyone is raving about the all-new beta.> >> > > > > > > ---------------------------------> Everyone is raving about the all-new beta.>Jackie

[Guest guest]

IF it was me and I was overweight,, as I was,, I WOULD ALWAYS chose Peg-Intron,, but if you are of normal weight, I dont think it matters as much which one.. the things I have read only said that Peg Intron was much more effective in Geno1's who WERE OVERWEIGHT....Sheena <mom4possums2002@...> wrote: I have a question, too, one that I've never really had answered, or else I didn't understand. As of right now, which drug company

has had the better results with obtaining remission in Genotype "1"s, Schering-Plough or Roche? I am still struggling along here.. right along, I'm sure with a few others... Thanks in Advance, Sheena <marvindamartian05 > wrote: hat does SAE stand for? -- In Hepatitis C , "elizabethnv1"<elizabethnv1@...> wrote:>> PegIntron/RBV Effective for >65 Year Olds> > Reported by Jules Levin> AASLD, Oct

27-31, 2006, Boston, MA> > “Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > and Well Tolerated in Patients >65 Years Old in Comparison to Other > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R > Trial)â€> > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. Pound,10 J. > Harvey,11 L. H. Griffel,11 C. A. Brass11> 1Northwestern University, Chicago, Illinois; 2Weill Medical College > of Cornell University, New York, New York; 3Columbia University > College of Medicine, New York, New York; 4Baptist Medical Center, > Kansas City, Missouri;> 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > 6Indiana University School of Medicine, Indianapolis, Indiana; > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; 8Austin >

Gastroenterology, PA, Austin, Texas;> 9California Pacific Medical Center, San Francisco, California; > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > AUTHOR CONCLUSIONS> Patients 18 to 25 years of age had the highest SVR rate (57%) among > the 6 age groups.> > The SVR rate in patients older than 65 years (46%) was similar to the > SVR rates observed in younger age groups (41%-57%).> > Although elderly patients tended to experience more AEs, the rate of > SAEs was similar in all groups, and the incidence of treatment > discontinuation in elderly patients was similar to or less than that > of younger patients.> > Data from this subanalysis of the WIN-R trial strongly suggest that > patients should not be denied antiviral therapy based on age alone.> >

> Abstract*> Background: Peg interferon (IFN) + ribavirin are the standard of care > for chronic HCV. There is reluctance to administer anti-viral > medications to older populations due to a fear of side effects and > possible decreased efficacy. Limited data is available on pts. age > >65 due to ineligibility for clinical trials. The role of age in > determining response to IFN-based antiviral therapy for chronic HCV > has not been clearly defined.> > Aim: To determine if age is an independent predictor of sustained > virological response (SVR) or medication tolerability within a > randomized, controlled clinical trial of treatment-naive pts. with > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > yrs., n=55.> > Methods: A retrospective review of the

multi-center WIN-R trial > database was undertaken. Pts. were randomized to receive PEG IFN 2b > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of therapy > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of therapy. > 4913 pts. received at least 1 dose of medication and are included in > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > pts. Were enrolled as protocol exceptions. Logistic regression > analyses of SVR comparing two age categories were performed. The > potential influence of demographic variables on SVR was evaluated > using the chi square test (two-way frequency table).> > Results: > The overall SVR was 44%. > > SVR rates for the grps were: > 18-25 yrs. = 57%, > 26-35 yrs. = 41% (p=0.02 vs 18-25),> 36-45 yrs. = 44% (p=0.03

vs 18-25), > 46-55 yrs. = 42%, > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > >65 yrs. SVR = 45%.> > There was no difference in SVR in any other pt. age grps including > pts. age >65 yrs. > > There were no differences in SAEs between all age groups. Pts. age 26-> 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in the 56-> 65 yrs. and the >65 yrs. age groups. > > Treatment discontinuations were significantly higher among the 26-35 > yrs. group when compared to two groups but there was no difference in > the treatment discontinuations in the >65 yrs. group compared with > any other.> > Conclusions: > 1) Adults age 18-25 yrs. had significantly increased chances of > obtaining SVR than most other age groups.> 2) Pts. >65 had similar SVR to all other age groups. > 3) Although there were more AEs in the

older age groups, the rate of > SAEs was the same and treatment drop-outs were the same or less than > the younger age groups. > 4) Pts. should not be denied anti-viral therapy based upon age alone.> > *Poster presents data updated since abstract submission.> > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> R) study was a prospective, multicenter, community and academic-> based, open-label, investigator-initiated, US clinical trial that > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > or weight-based ribavirin in treatment-naive patients with chronic > hepatitis C.> - Overall SVR rates were 44% in the weight-based ribavirin arm and > 41% in the flat-dose ribavirin arm (P = .020).3> - SVR rates in patients with chronic hepatitis C caused by hepatitis > C virus (HCV) genotype 1 (G1) were 34% and 29%,

respectively (P > =.004).3> - Weight-based ribavirin dosing was associated with higher rates of > dose reduction for anemia but not with higher rates of > discontinuation.3> Everyone is raving about the all-new beta. Jackie

[Guest guest]

well I think it means your BMI and I think if your BMI is high enough to be classified as Obese.. I am obese even tho most ppl dont think I weigh what I weigh... how tall are you? 30 pounds just might classify you as obese depending on how tall you are.. <marvindamartian05@...> wrote: Please define "overweight". I am serious here really....I am about 20lbs overweight right now (based on how I consider that I look my best)but if you go by BMI, I am about 30 lbs overweight. Does overweightmean, 5

lbs, 10 lbs, 50 lbs....?> >> > PegIntron/RBV Effective for >65 Year Olds>

> > > Reported by Jules Levin> > AASLD, Oct 27-31, 2006, Boston, MA> > > > “Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > > and Well Tolerated in Patients >65 Years Old in Comparison to Other > > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R > > Trial)â€> > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. Pound,10 J. > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > 1Northwestern University, Chicago, Illinois; 2Weill Medical College > > of Cornell University, New York, New York; 3Columbia University > > College of Medicine, New York, New York; 4Baptist Medical Center, > > Kansas City, Missouri;> > 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > > 6Indiana University

School of Medicine, Indianapolis, Indiana; > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; 8Austin > > Gastroenterology, PA, Austin, Texas;> > 9California Pacific Medical Center, San Francisco, California; > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > AUTHOR CONCLUSIONS> > Patients 18 to 25 years of age had the highest SVR rate (57%) among > > the 6 age groups.> > > > The SVR rate in patients older than 65 years (46%) was similar to the > > SVR rates observed in younger age groups (41%-57%).> > > > Although elderly patients tended to experience more AEs, the rate of > > SAEs was similar in all groups, and the incidence of treatment > > discontinuation in elderly patients was similar to or less than that

> > of younger patients.> > > > Data from this subanalysis of the WIN-R trial strongly suggest that > > patients should not be denied antiviral therapy based on age alone.> > > > > > Abstract*> > Background: Peg interferon (IFN) + ribavirin are the standard of care > > for chronic HCV. There is reluctance to administer anti-viral > > medications to older populations due to a fear of side effects and > > possible decreased efficacy. Limited data is available on pts. age > > >65 due to ineligibility for clinical trials. The role of age in > > determining response to IFN-based antiviral therapy for chronic HCV > > has not been clearly defined.> > > > Aim: To determine if age is an independent predictor of sustained > > virological response (SVR) or medication tolerability within a > > randomized,

controlled clinical trial of treatment-naive pts. with > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > > yrs., n=55.> > > > Methods: A retrospective review of the multi-center WIN-R trial > > database was undertaken. Pts. were randomized to receive PEG IFN 2b > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of therapy > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of therapy. > > 4913 pts. received at least 1 dose of medication and are included in > > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > > pts. Were enrolled as protocol exceptions. Logistic regression > > analyses of SVR comparing two age categories were performed.

The > > potential influence of demographic variables on SVR was evaluated > > using the chi square test (two-way frequency table).> > > > Results: > > The overall SVR was 44%. > > > > SVR rates for the grps were: > > 18-25 yrs. = 57%, > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > 46-55 yrs. = 42%, > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > > >65 yrs. SVR = 45%.> > > > There was no difference in SVR in any other pt. age grps including > > pts. age >65 yrs. > > > > There were no differences in SAEs between all age groups. Pts. age 26-> > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in the 56-> > 65 yrs. and the >65 yrs. age groups. > > > > Treatment discontinuations were significantly higher

among the 26-35 > > yrs. group when compared to two groups but there was no difference in > > the treatment discontinuations in the >65 yrs. group compared with > > any other.> > > > Conclusions: > > 1) Adults age 18-25 yrs. had significantly increased chances of > > obtaining SVR than most other age groups.> > 2) Pts. >65 had similar SVR to all other age groups. > > 3) Although there were more AEs in the older age groups, the rate of > > SAEs was the same and treatment drop-outs were the same or less than > > the younger age groups. > > 4) Pts. should not be denied anti-viral therapy based upon age alone.> > > > *Poster presents data updated since abstract submission.> > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> > R) study was a prospective, multicenter,

community and academic-> > based, open-label, investigator-initiated, US clinical trial that > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > > or weight-based ribavirin in treatment-naive patients with chronic > > hepatitis C.> > - Overall SVR rates were 44% in the weight-based ribavirin arm and > > 41% in the flat-dose ribavirin arm (P = .020).3> > - SVR rates in patients with chronic hepatitis C caused by hepatitis > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P > > =.004).3> > - Weight-based ribavirin dosing was associated with higher rates of > > dose reduction for anemia but not with higher rates of > > discontinuation.3> >> > > > > > ---------------------------------> Everyone is raving about the all-new beta.

> > > > > > > Jackie>Jackie

[Guest guest]

I am 5' 2 " and about 155 lbs. I was 165 when I was diagnosed, and my

detoxing and improved diet, not to mention stopping drinking both

alcohol and soda the minute I learned I had Hep C, got about 10 lbs

off in the last 2 months. My pants are hanging off me now. My goal is

to be down to 140 when I start tx. But my acupuncturist says I should

be about 115, but I will look emaciated at that weight - I know this

from past experience. I really do have " big bones " and they will stick

out at 115...maybe this is a good thing?

Whatever I have to do to increase my odds, I will do!

> > >

> > > PegIntron/RBV Effective for >65 Year Olds

> > >

> > > Reported by Jules Levin

> > > AASLD, Oct 27-31, 2006, Boston, MA

> > >

> > > “Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious

> > > and Well Tolerated in Patients >65 Years Old in Comparison to Other

> > > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R

> > > Trial)â€

> > >

> > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N.

> > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

Pound,10 J.

> > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > 1Northwestern University, Chicago, Illinois; 2Weill Medical College

> > > of Cornell University, New York, New York; 3Columbia University

> > > College of Medicine, New York, New York; 4Baptist Medical Center,

> > > Kansas City, Missouri;

> > > 5Beth Israel Deaconness Medical Center, Boston, Massachusetts;

> > > 6Indiana University School of Medicine, Indianapolis, Indiana;

> > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;

8Austin

> > > Gastroenterology, PA, Austin, Texas;

> > > 9California Pacific Medical Center, San Francisco, California;

> > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana;

> > > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> > >

> > > AUTHOR CONCLUSIONS

> > > Patients 18 to 25 years of age had the highest SVR rate (57%) among

> > > the 6 age groups.

> > >

> > > The SVR rate in patients older than 65 years (46%) was similar

to the

> > > SVR rates observed in younger age groups (41%-57%).

> > >

> > > Although elderly patients tended to experience more AEs, the

rate of

> > > SAEs was similar in all groups, and the incidence of treatment

> > > discontinuation in elderly patients was similar to or less than

that

> > > of younger patients.

> > >

> > > Data from this subanalysis of the WIN-R trial strongly suggest that

> > > patients should not be denied antiviral therapy based on age alone.

> > >

> > >

> > > Abstract*

> > > Background: Peg interferon (IFN) + ribavirin are the standard of

care

> > > for chronic HCV. There is reluctance to administer anti-viral

> > > medications to older populations due to a fear of side effects and

> > > possible decreased efficacy. Limited data is available on pts. age

> > > >65 due to ineligibility for clinical trials. The role of age in

> > > determining response to IFN-based antiviral therapy for chronic HCV

> > > has not been clearly defined.

> > >

> > > Aim: To determine if age is an independent predictor of sustained

> > > virological response (SVR) or medication tolerability within a

> > > randomized, controlled clinical trial of treatment-naive pts. with

> > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350;

> > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65

> > > yrs., n=55.

> > >

> > > Methods: A retrospective review of the multi-center WIN-R trial

> > > database was undertaken. Pts. were randomized to receive PEG IFN 2b

> > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400

> > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of

therapy

> > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of

therapy.

> > > 4913 pts. received at least 1 dose of medication and are

included in

> > > this analysis. Although pts. age >65 yrs. were ineligible, 55 such

> > > pts. Were enrolled as protocol exceptions. Logistic regression

> > > analyses of SVR comparing two age categories were performed. The

> > > potential influence of demographic variables on SVR was evaluated

> > > using the chi square test (two-way frequency table).

> > >

> > > Results:

> > > The overall SVR was 44%.

> > >

> > > SVR rates for the grps were:

> > > 18-25 yrs. = 57%,

> > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > 46-55 yrs. = 42%,

> > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for

> > > >65 yrs. SVR = 45%.

> > >

> > > There was no difference in SVR in any other pt. age grps including

> > > pts. age >65 yrs.

> > >

> > > There were no differences in SAEs between all age groups. Pts.

age 26-

> > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in

the 56-

> > > 65 yrs. and the >65 yrs. age groups.

> > >

> > > Treatment discontinuations were significantly higher among the

26-35

> > > yrs. group when compared to two groups but there was no

difference in

> > > the treatment discontinuations in the >65 yrs. group compared with

> > > any other.

> > >

> > > Conclusions:

> > > 1) Adults age 18-25 yrs. had significantly increased chances of

> > > obtaining SVR than most other age groups.

> > > 2) Pts. >65 had similar SVR to all other age groups.

> > > 3) Although there were more AEs in the older age groups, the

rate of

> > > SAEs was the same and treatment drop-outs were the same or less

than

> > > the younger age groups.

> > > 4) Pts. should not be denied anti-viral therapy based upon age

alone.

> > >

> > > *Poster presents data updated since abstract submission.

> > >

> > >

> > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-

> > > R) study was a prospective, multicenter, community and academic-

> > > based, open-label, investigator-initiated, US clinical trial that

> > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose

> > > or weight-based ribavirin in treatment-naive patients with chronic

> > > hepatitis C.

> > > - Overall SVR rates were 44% in the weight-based ribavirin arm and

> > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > - SVR rates in patients with chronic hepatitis C caused by

hepatitis

> > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P

> > > =.004).3

> > > - Weight-based ribavirin dosing was associated with higher rates of

> > > dose reduction for anemia but not with higher rates of

> > > discontinuation.3

> > >

> >

> >

> >

> >

> >

> > ---------------------------------

> > Everyone is raving about the all-new beta.

> >

> >

> >

> >

> >

> >

> > Jackie

> >

>

>

>

>

>

>

> Jackie

>

[Guest guest]

It's on the Valeant website, as " ribavirin for inhalation USP....

VIRAZOLE® is indicated for the treatment of hospitalized infants and

young children with severe lower respiratory tract infections due to

Respiratory Syncytial Virus (RSV). Treatment early in the course of

severe lower respiratory tract infection may be necessary to achieve

efficacy. "

So, basically it's the same ribavirin, but made in this form because

it's easier to give to babies, for respiratory viral infections. I

wonder why they don't make it as inhalant for Hep C treatment too?

Because then it would bypass the liver and go directly into the blood

stream without causing the liver extra work to process it. Or, it

could be put into a patch form, I suppose.

Obviously, I have no medical background but it seems to make sense to

make meds to treat liver diseases in a form most benign to the liver

itself. I'm sure I'm missing something here. I just don't like to take

pills, so maybe that's my angle.

> > > >

> > > > PegIntron/RBV Effective for >65 Year Olds

> > > >

> > > > Reported by Jules Levin

> > > > AASLD, Oct 27-31, 2006, Boston, MA

> > > >

> > > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally

> > Efficacious

> > > > and Well Tolerated in Patients >65 Years Old in Comparison to

> > Other

> > > > Age Groups: Subanalysis of a Randomized, Controlled Study

> > (WIN-R

> > > > Trial)â?

> > > >

> > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N.

> > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> > Pound,10 J.

> > > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > > 1Northwestern University, Chicago, Illinois; 2Weill Medical

> > College

> > > > of Cornell University, New York, New York; 3Columbia

> > University

> > > > College of Medicine, New York, New York; 4Baptist Medical

> > Center,

> > > > Kansas City, Missouri;

> > > > 5Beth Israel Deaconness Medical Center, Boston,

> > Massachusetts;

> > > > 6Indiana University School of Medicine, Indianapolis,

> > Indiana;

> > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;

> > 8Austin

> > > > Gastroenterology, PA, Austin, Texas;

> > > > 9California Pacific Medical Center, San Francisco,

> > California;

> > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana;

> > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> > > >

> > > > AUTHOR CONCLUSIONS

> > > > Patients 18 to 25 years of age had the highest SVR rate (57%)

> > among

> > > > the 6 age groups.

> > > >

> > > > The SVR rate in patients older than 65 years (46%) was

> > similar to the

> > > > SVR rates observed in younger age groups (41%-57%).

> > > >

> > > > Although elderly patients tended to experience more AEs, the

> > rate of

> > > > SAEs was similar in all groups, and the incidence of

> > treatment

> > > > discontinuation in elderly patients was similar to or less

> > than that

> > > > of younger patients.

> > > >

> > > > Data from this subanalysis of the WIN-R trial strongly

> > suggest that

> > > > patients should not be denied antiviral therapy based on age

> > alone.

> > > >

> > > >

> > > > Abstract*

> > > > Background: Peg interferon (IFN) + ribavirin are the standard

> > of care

> > > > for chronic HCV. There is reluctance to administer anti-viral

> > > > medications to older populations due to a fear of side

> > effects and

> > > > possible decreased efficacy. Limited data is available on

> > pts. age

> > > > >65 due to ineligibility for clinical trials. The role of age

> > in

> > > > determining response to IFN-based antiviral therapy for

> > chronic HCV

> > > > has not been clearly defined.

> > > >

> > > > Aim: To determine if age is an independent predictor of

> > sustained

> > > > virological response (SVR) or medication tolerability within

> > a

> > > > randomized, controlled clinical trial of treatment-naive pts.

> > with

> > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs.,

> > n=350;

> > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

> > and >65

> > > > yrs., n=55.

> > > >

> > > > Methods: A retrospective review of the multi-center WIN-R

> > trial

> > > > database was undertaken. Pts. were randomized to receive PEG

> > IFN 2b

> > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-

> > 1400

> > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of

> > therapy

> > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of

> > therapy.

> > > > 4913 pts. received at least 1 dose of medication and are

> > included in

> > > > this analysis. Although pts. age >65 yrs. were ineligible, 55

> > such

> > > > pts. Were enrolled as protocol exceptions. Logistic

> > regression

> > > > analyses of SVR comparing two age categories were performed.

> > The

> > > > potential influence of demographic variables on SVR was

> > evaluated

> > > > using the chi square test (two-way frequency table).

> > > >

> > > > Results:

> > > > The overall SVR was 44%.

> > > >

> > > > SVR rates for the grps were:

> > > > 18-25 yrs. = 57%,

> > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > > 46-55 yrs. = 42%,

> > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for

> > > > >65 yrs. SVR = 45%.

> > > >

> > > > There was no difference in SVR in any other pt. age grps

> > including

> > > > pts. age >65 yrs.

> > > >

> > > > There were no differences in SAEs between all age groups.

> > Pts. age 26-

> > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those

> > in the 56-

> > > > 65 yrs. and the >65 yrs. age groups.

> > > >

> > > > Treatment discontinuations were significantly higher among

> > the 26-35

> > > > yrs. group when compared to two groups but there was no

> > difference in

> > > > the treatment discontinuations in the >65 yrs. group compared

> > with

> > > > any other.

> > > >

> > > > Conclusions:

> > > > 1) Adults age 18-25 yrs. had significantly increased chances

> > of

> > > > obtaining SVR than most other age groups.

> > > > 2) Pts. >65 had similar SVR to all other age groups.

> > > > 3) Although there were more AEs in the older age groups, the

> > rate of

> > > > SAEs was the same and treatment drop-outs were the same or

> > less than

> > > > the younger age groups.

> > > > 4) Pts. should not be denied anti-viral therapy based upon

> > age alone.

> > > >

> > > > *Poster presents data updated since abstract submission.

> > > >

> > > >

> > > > The Weight-Based Dosing of Peginterferon alfa-2b and

> > Ribavirin (WIN-

> > > > R) study was a prospective, multicenter, community and

> > academic-

> > > > based, open-label, investigator-initiated, US clinical trial

> > that

> > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

> > flat-dose

> > > > or weight-based ribavirin in treatment-naive patients with

> > chronic

> > > > hepatitis C.

> > > > - Overall SVR rates were 44% in the weight-based ribavirin

> > arm and

> > > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > > - SVR rates in patients with chronic hepatitis C caused by

> > hepatitis

> > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively

> > (P

> > > > =.004).3

> > > > - Weight-based ribavirin dosing was associated with higher

> > rates of

> > > > dose reduction for anemia but not with higher rates of

> > > > discontinuation.3

> > > >

> > >

> > >

> > >

> > >

> > >

> > >

> > > ----------------------------------------------------------

> > ----------

> > > Everyone is raving about the all-new beta.

> > >

> >

> >

> >

> >

> >

> >

> > ---------------------------------

> > Everyone is raving about the all-new beta.

> >

>

>

>

>

>

>

> Jackie

>

[Guest guest]

It is also called Tribaviron , it is used for infants with rsv . It is a synthectic antiviral medication , and so far I know they are not using it for hep c treatment .

Re: Another Question

Hey, there is something called Virazole, which it says is an inhalantversion of Ribavarin. anyone have any experience with this?> > >> > > PegIntron/RBV Effective for >65 Year Olds> > > > > > Reported by Jules Levin> > > AASLD, Oct 27-31, 2006, Boston, MA> > > > > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally > Efficacious > > > and Well Tolerated in Patients >65 Years Old in Comparison to > Other > > > Age Groups: Subanalysis of a Randomized, Controlled Study > (WIN-R > > > Trial)â?> > > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. > Pound,10 J. > > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > > 1Northwestern University, Chicago, Illinois; 2Weill Medical > College > > > of Cornell University, New York, New York; 3Columbia > University > > > College of Medicine, New York, New York; 4Baptist Medical > Center, > > > Kansas City, Missouri;> > > 5Beth Israel Deaconness Medical Center, Boston, > Massachusetts; > > > 6Indiana University School of Medicine, Indianapolis, > Indiana; > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; > 8Austin > > > Gastroenterology, PA, Austin, Texas;> > > 9California Pacific Medical Center, San Francisco, > California; > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > > > AUTHOR CONCLUSIONS> > > Patients 18 to 25 years of age had the highest SVR rate (57%) > among > > > the 6 age groups.> > > > > > The SVR rate in patients older than 65 years (46%) was > similar to the > > > SVR rates observed in younger age groups (41%-57%).> > > > > > Although elderly patients tended to experience more AEs, the > rate of > > > SAEs was similar in all groups, and the incidence of > treatment > > > discontinuation in elderly patients was similar to or less > than that > > > of younger patients.> > > > > > Data from this subanalysis of the WIN-R trial strongly > suggest that > > > patients should not be denied antiviral therapy based on age > alone.> > > > > > > > > Abstract*> > > Background: Peg interferon (IFN) + ribavirin are the standard > of care > > > for chronic HCV. There is reluctance to administer anti-viral > > > medications to older populations due to a fear of side > effects and > > > possible decreased efficacy. Limited data is available on > pts. age > > > >65 due to ineligibility for clinical trials. The role of age > in > > > determining response to IFN-based antiviral therapy for > chronic HCV > > > has not been clearly defined.> > > > > > Aim: To determine if age is an independent predictor of > sustained > > > virological response (SVR) or medication tolerability within > a > > > randomized, controlled clinical trial of treatment-naive pts. > with > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., > n=350; > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; > and >65 > > > yrs., n=55.> > > > > > Methods: A retrospective review of the multi-center WIN-R > trial > > > database was undertaken. Pts. were randomized to receive PEG > IFN 2b > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-> 1400 > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of > therapy > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of > therapy. > > > 4913 pts. received at least 1 dose of medication and are > included in > > > this analysis. Although pts. age >65 yrs. were ineligible, 55 > such > > > pts. Were enrolled as protocol exceptions. Logistic > regression > > > analyses of SVR comparing two age categories were performed. > The > > > potential influence of demographic variables on SVR was > evaluated > > > using the chi square test (two-way frequency table).> > > > > > Results: > > > The overall SVR was 44%. > > > > > > SVR rates for the grps were: > > > 18-25 yrs. = 57%, > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > > 46-55 yrs. = 42%, > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > > > >65 yrs. SVR = 45%.> > > > > > There was no difference in SVR in any other pt. age grps > including > > > pts. age >65 yrs. > > > > > > There were no differences in SAEs between all age groups. > Pts. age 26-> > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those > in the 56-> > > 65 yrs. and the >65 yrs. age groups. > > > > > > Treatment discontinuations were significantly higher among > the 26-35 > > > yrs. group when compared to two groups but there was no > difference in > > > the treatment discontinuations in the >65 yrs. group compared > with > > > any other.> > > > > > Conclusions: > > > 1) Adults age 18-25 yrs. had significantly increased chances > of > > > obtaining SVR than most other age groups.> > > 2) Pts. >65 had similar SVR to all other age groups. > > > 3) Although there were more AEs in the older age groups, the > rate of > > > SAEs was the same and treatment drop-outs were the same or > less than > > > the younger age groups. > > > 4) Pts. should not be denied anti-viral therapy based upon > age alone.> > > > > > *Poster presents data updated since abstract submission.> > > > > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and > Ribavirin (WIN-> > > R) study was a prospective, multicenter, community and > academic-> > > based, open-label, investigator-initiated, US clinical trial > that > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus > flat-dose > > > or weight-based ribavirin in treatment-naive patients with > chronic > > > hepatitis C.> > > - Overall SVR rates were 44% in the weight-based ribavirin > arm and > > > 41% in the flat-dose ribavirin arm (P = .020).3> > > - SVR rates in patients with chronic hepatitis C caused by > hepatitis > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively > (P > > > =.004).3> > > - Weight-based ribavirin dosing was associated with higher > rates of > > > dose reduction for anemia but not with higher rates of > > > discontinuation.3> > >> > > > > > > > > > > > > > ----------------------------------------------------------> ----------> > Everyone is raving about the all-new beta.> >> > > > > > > ---------------------------------> Everyone is raving about the all-new beta.>

[Guest guest]

well I'd bet as an inhalent you wouldnt be able to get enough to keep your blood levels stabilized or enough to kill this kind of virus,, RSV is a lung virus so by inhaling it , it goes straight to the virus,, but HEP is in the blood so it wouldnt probably be the same as effect goes,, <marvindamartian05@...> wrote: It's on the Valeant website, as "ribavirin for inhalation USP....VIRAZOLE® is indicated for the treatment of hospitalized infants andyoung children with severe lower respiratory tract infections

due toRespiratory Syncytial Virus (RSV). Treatment early in the course ofsevere lower respiratory tract infection may be necessary to achieveefficacy."So, basically it's the same ribavirin, but made in this form becauseit's easier to give to babies, for respiratory viral infections. Iwonder why they don't make it as inhalant for Hep C treatment too?Because then it would bypass the liver and go directly into the bloodstream without causing the liver extra work to process it. Or, itcould be put into a patch form, I suppose.Obviously, I have no medical background but it seems to make sense tomake meds to treat liver diseases in a form most benign to the liveritself. I'm sure I'm missing something here. I just don't like to takepills, so maybe that's my angle. > > > >> > > >

PegIntron/RBV Effective for >65 Year Olds> > > > > > > > Reported by Jules Levin> > > > AASLD, Oct 27-31, 2006, Boston, MA> > > > > > > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally > > Efficacious > > > > and Well Tolerated in Patients >65 Years Old in Comparison to > > Other > > > > Age Groups: Subanalysis of a Randomized, Controlled Study > > (WIN-R > > > > Trial)â?> > > > > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. > > Pound,10 J. > > > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > > > 1Northwestern University, Chicago, Illinois; 2Weill Medical > > College > > > > of Cornell University, New

York, New York; 3Columbia > > University > > > > College of Medicine, New York, New York; 4Baptist Medical > > Center, > > > > Kansas City, Missouri;> > > > 5Beth Israel Deaconness Medical Center, Boston, > > Massachusetts; > > > > 6Indiana University School of Medicine, Indianapolis, > > Indiana; > > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; > > 8Austin > > > > Gastroenterology, PA, Austin, Texas;> > > > 9California Pacific Medical Center, San Francisco, > > California; > > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > > > > > AUTHOR CONCLUSIONS> > > > Patients 18 to 25 years of age had the highest SVR rate

(57%) > > among > > > > the 6 age groups.> > > > > > > > The SVR rate in patients older than 65 years (46%) was > > similar to the > > > > SVR rates observed in younger age groups (41%-57%).> > > > > > > > Although elderly patients tended to experience more AEs, the > > rate of > > > > SAEs was similar in all groups, and the incidence of > > treatment > > > > discontinuation in elderly patients was similar to or less > > than that > > > > of younger patients.> > > > > > > > Data from this subanalysis of the WIN-R trial strongly > > suggest that > > > > patients should not be denied antiviral therapy based on age > > alone.> > > > > > > > > > > > Abstract*> >

> > Background: Peg interferon (IFN) + ribavirin are the standard > > of care > > > > for chronic HCV. There is reluctance to administer anti-viral > > > > medications to older populations due to a fear of side > > effects and > > > > possible decreased efficacy. Limited data is available on > > pts. age > > > > >65 due to ineligibility for clinical trials. The role of age > > in > > > > determining response to IFN-based antiviral therapy for > > chronic HCV > > > > has not been clearly defined.> > > > > > > > Aim: To determine if age is an independent predictor of > > sustained > > > > virological response (SVR) or medication tolerability within > > a > > > > randomized, controlled clinical trial of treatment-naive pts. > >

with > > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., > > n=350; > > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; > > and >65 > > > > yrs., n=55.> > > > > > > > Methods: A retrospective review of the multi-center WIN-R > > trial > > > > database was undertaken. Pts. were randomized to receive PEG > > IFN 2b > > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-> > 1400 > > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of > > therapy > > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of > > therapy. > > > > 4913 pts. received at least 1 dose of medication and are > > included in > > > > this analysis. Although pts. age >65 yrs. were

ineligible, 55 > > such > > > > pts. Were enrolled as protocol exceptions. Logistic > > regression > > > > analyses of SVR comparing two age categories were performed. > > The > > > > potential influence of demographic variables on SVR was > > evaluated > > > > using the chi square test (two-way frequency table).> > > > > > > > Results: > > > > The overall SVR was 44%. > > > > > > > > SVR rates for the grps were: > > > > 18-25 yrs. = 57%, > > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > > > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > > > 46-55 yrs. = 42%, > > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > > > > >65 yrs. SVR = 45%.> > > > > > > > There was no

difference in SVR in any other pt. age grps > > including > > > > pts. age >65 yrs. > > > > > > > > There were no differences in SAEs between all age groups. > > Pts. age 26-> > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those > > in the 56-> > > > 65 yrs. and the >65 yrs. age groups. > > > > > > > > Treatment discontinuations were significantly higher among > > the 26-35 > > > > yrs. group when compared to two groups but there was no > > difference in > > > > the treatment discontinuations in the >65 yrs. group compared > > with > > > > any other.> > > > > > > > Conclusions: > > > > 1) Adults age 18-25 yrs. had significantly increased chances > > of > > > >

obtaining SVR than most other age groups.> > > > 2) Pts. >65 had similar SVR to all other age groups. > > > > 3) Although there were more AEs in the older age groups, the > > rate of > > > > SAEs was the same and treatment drop-outs were the same or > > less than > > > > the younger age groups. > > > > 4) Pts. should not be denied anti-viral therapy based upon > > age alone.> > > > > > > > *Poster presents data updated since abstract submission.> > > > > > > > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and > > Ribavirin (WIN-> > > > R) study was a prospective, multicenter, community and > > academic-> > > > based, open-label, investigator-initiated, US clinical trial > > that > > > >

evaluated the efficacy and safety of PEG-IFN alfa-2b plus > > flat-dose > > > > or weight-based ribavirin in treatment-naive patients with > > chronic > > > > hepatitis C.> > > > - Overall SVR rates were 44% in the weight-based ribavirin > > arm and > > > > 41% in the flat-dose ribavirin arm (P = .020).3> > > > - SVR rates in patients with chronic hepatitis C caused by > > hepatitis > > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively > > (P > > > > =.004).3> > > > - Weight-based ribavirin dosing was associated with higher > > rates of > > > > dose reduction for anemia but not with higher rates of > > > > discontinuation.3> > > >> > > > > > > > > > > > > >

> > > > > > > ----------------------------------------------------------> > ----------> > > Everyone is raving about the all-new beta.> > >> > > > > > > > > > > > > > ---------------------------------> > Everyone is raving about the all-new beta.> >> > > > > > > Jackie>Jackie

[Guest guest]

well I would think that you should discuss with your doc about doing the peg intron if your insurance covers that one... well thats what I'd do if it was me,, but you have to do whatever your doc recommends <marvindamartian05@...> wrote: I am 5' 2" and about 155 lbs. I was 165 when I was diagnosed, and mydetoxing and improved diet, not to mention stopping drinking bothalcohol and soda the minute I learned I had Hep C, got about 10 lbsoff in the last 2 months. My pants are hanging off me now. My goal

isto be down to 140 when I start tx. But my acupuncturist says I shouldbe about 115, but I will look emaciated at that weight - I know thisfrom past experience. I really do have "big bones" and they will stickout at 115...maybe this is a good thing?Whatever I have to do to increase my odds, I will do!> > >> > > PegIntron/RBV Effective for >65 Year Olds> > > > > > Reported by Jules Levin> > > AASLD, Oct 27-31, 2006, Boston, MA> > > > > > “Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > > > and Well Tolerated in Patients >65 Years Old in Comparison to Other > > > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R > > > Trial)â€> > > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.Pound,10 J. > > > Harvey,11 L.

H. Griffel,11 C. A. Brass11> > > 1Northwestern University, Chicago, Illinois; 2Weill Medical College > > > of Cornell University, New York, New York; 3Columbia University > > > College of Medicine, New York, New York; 4Baptist Medical Center, > > > Kansas City, Missouri;> > > 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > > > 6Indiana University School of Medicine, Indianapolis, Indiana; > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;8Austin > > > Gastroenterology, PA, Austin, Texas;> > > 9California Pacific Medical Center, San Francisco, California; > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > > > AUTHOR CONCLUSIONS> > > Patients 18 to 25 years of age had

the highest SVR rate (57%) among > > > the 6 age groups.> > > > > > The SVR rate in patients older than 65 years (46%) was similarto the > > > SVR rates observed in younger age groups (41%-57%).> > > > > > Although elderly patients tended to experience more AEs, therate of > > > SAEs was similar in all groups, and the incidence of treatment > > > discontinuation in elderly patients was similar to or less thanthat > > > of younger patients.> > > > > > Data from this subanalysis of the WIN-R trial strongly suggest that > > > patients should not be denied antiviral therapy based on age alone.> > > > > > > > > Abstract*> > > Background: Peg interferon (IFN) + ribavirin are the standard ofcare > > > for chronic HCV. There is reluctance to

administer anti-viral > > > medications to older populations due to a fear of side effects and > > > possible decreased efficacy. Limited data is available on pts. age > > > >65 due to ineligibility for clinical trials. The role of age in > > > determining response to IFN-based antiviral therapy for chronic HCV > > > has not been clearly defined.> > > > > > Aim: To determine if age is an independent predictor of sustained > > > virological response (SVR) or medication tolerability within a > > > randomized, controlled clinical trial of treatment-naive pts. with > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > > > yrs., n=55.> > > > > > Methods: A retrospective review of the multi-center

WIN-R trial > > > database was undertaken. Pts. were randomized to receive PEG IFN 2b > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks oftherapy > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks oftherapy. > > > 4913 pts. received at least 1 dose of medication and areincluded in > > > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > > > pts. Were enrolled as protocol exceptions. Logistic regression > > > analyses of SVR comparing two age categories were performed. The > > > potential influence of demographic variables on SVR was evaluated > > > using the chi square test (two-way frequency table).> > > > > > Results: > > > The overall SVR was 44%. > > >

> > > SVR rates for the grps were: > > > 18-25 yrs. = 57%, > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > > 46-55 yrs. = 42%, > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > > > >65 yrs. SVR = 45%.> > > > > > There was no difference in SVR in any other pt. age grps including > > > pts. age >65 yrs. > > > > > > There were no differences in SAEs between all age groups. Pts.age 26-> > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those inthe 56-> > > 65 yrs. and the >65 yrs. age groups. > > > > > > Treatment discontinuations were significantly higher among the26-35 > > > yrs. group when compared to two groups but there was nodifference in > > > the treatment

discontinuations in the >65 yrs. group compared with > > > any other.> > > > > > Conclusions: > > > 1) Adults age 18-25 yrs. had significantly increased chances of > > > obtaining SVR than most other age groups.> > > 2) Pts. >65 had similar SVR to all other age groups. > > > 3) Although there were more AEs in the older age groups, therate of > > > SAEs was the same and treatment drop-outs were the same or lessthan > > > the younger age groups. > > > 4) Pts. should not be denied anti-viral therapy based upon agealone.> > > > > > *Poster presents data updated since abstract submission.> > > > > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> > > R) study was a prospective, multicenter, community and academic-> >

> based, open-label, investigator-initiated, US clinical trial that > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > > > or weight-based ribavirin in treatment-naive patients with chronic > > > hepatitis C.> > > - Overall SVR rates were 44% in the weight-based ribavirin arm and > > > 41% in the flat-dose ribavirin arm (P = .020).3> > > - SVR rates in patients with chronic hepatitis C caused byhepatitis > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P > > > =.004).3> > > - Weight-based ribavirin dosing was associated with higher rates of > > > dose reduction for anemia but not with higher rates of > > > discontinuation.3> > >> > > > > > > > > > > >

---------------------------------> > Everyone is raving about the all-new beta. > > > > > > > > > > > > > > Jackie> >> > > > > > > Jackie>Jackie

[Guest guest]

, 115 sounds seriously underweight. You shouldn't go by BMI anyway as it doesn't take muscle mass into account whatsoever. I am 5'1 " and weigh around 132 and am NOT overweight because muscle weighs much more then fat. If I go by BMI then it says that I am very overweight. I got down to 122 at one time and ended up seriously risking my health because of being underweight, yes 122 at 5'1 " is way underweight for me. The best thing to do is have your body fat % checked then determine your weight based on that.

Ally

On 11/10/06, <marvindamartian05@...> wrote:

I am 5' 2 " and about 155 lbs. I was 165 when I was diagnosed, and mydetoxing and improved diet, not to mention stopping drinking bothalcohol and soda the minute I learned I had Hep C, got about 10 lbs

off in the last 2 months. My pants are hanging off me now. My goal isto be down to 140 when I start tx. But my acupuncturist says I shouldbe about 115, but I will look emaciated at that weight - I know thisfrom past experience. I really do have " big bones " and they will stick

out at 115...maybe this is a good thing?Whatever I have to do to increase my odds, I will do!> > >> > > PegIntron/RBV Effective for >65 Year Olds> > > > > > Reported by Jules Levin

> > > AASLD, Oct 27-31, 2006, Boston, MA> > > > > > "Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > > > and Well Tolerated in Patients >65 Years Old in Comparison to Other > > > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R > > > Trial)"> > > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

Pound,10 J. > > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > > 1Northwestern University, Chicago, Illinois; 2Weill Medical College > > > of Cornell University, New York, New York; 3Columbia University > > > College of Medicine, New York, New York; 4Baptist Medical Center, > > > Kansas City, Missouri;> > > 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > > > 6Indiana University School of Medicine, Indianapolis, Indiana; > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;8Austin > > > Gastroenterology, PA, Austin, Texas;> > > 9California Pacific Medical Center, San Francisco, California; > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > > > AUTHOR CONCLUSIONS> > > Patients 18 to 25 years of age had the highest SVR rate (57%) among > > > the 6 age groups.> > > > > > The SVR rate in patients older than 65 years (46%) was similarto the > > > SVR rates observed in younger age groups (41%-57%).

> > > > > > Although elderly patients tended to experience more AEs, therate of > > > SAEs was similar in all groups, and the incidence of treatment > > > discontinuation in elderly patients was similar to or less than

that > > > of younger patients.> > > > > > Data from this subanalysis of the WIN-R trial strongly suggest that > > > patients should not be denied antiviral therapy based on age alone.

> > > > > > > > > Abstract*> > > Background: Peg interferon (IFN) + ribavirin are the standard ofcare > > > for chronic HCV. There is reluctance to administer anti-viral > > > medications to older populations due to a fear of side effects and > > > possible decreased efficacy. Limited data is available on pts. age > > > >65 due to ineligibility for clinical trials. The role of age in > > > determining response to IFN-based antiviral therapy for chronic HCV > > > has not been clearly defined.> > > > > > Aim: To determine if age is an independent predictor of sustained > > > virological response (SVR) or medication tolerability within a > > > randomized, controlled clinical trial of treatment-naive pts. with > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > > > yrs., n=55.> > > > > > Methods: A retrospective review of the multi-center WIN-R trial > > > database was undertaken. Pts. were randomized to receive PEG IFN 2b > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of

therapy > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks oftherapy. > > > 4913 pts. received at least 1 dose of medication and areincluded in > > > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > > > pts. Were enrolled as protocol exceptions. Logistic regression > > > analyses of SVR comparing two age categories were performed. The > > > potential influence of demographic variables on SVR was evaluated > > > using the chi square test (two-way frequency table).> > > > > > Results: > > > The overall SVR was 44%. > > > > > > SVR rates for the grps were: > > > 18-25 yrs. = 57%, > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > > 46-55 yrs. = 42%, > > > 56-65 yrs. = 40% (p=

0.01 vs 18-25) and for > > > >65 yrs. SVR = 45%.> > > > > > There was no difference in SVR in any other pt. age grps including > > > pts. age >65 yrs. > > > > > > There were no differences in SAEs between all age groups. Pts.age 26-> > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those inthe 56-> > > 65 yrs. and the >65 yrs. age groups. > > > > > > Treatment discontinuations were significantly higher among the26-35 > > > yrs. group when compared to two groups but there was nodifference in > > > the treatment discontinuations in the >65 yrs. group compared with > > > any other.> > > > > > Conclusions: > > > 1) Adults age 18-25 yrs. had significantly increased chances of > > > obtaining SVR than most other age groups.

> > > 2) Pts. >65 had similar SVR to all other age groups. > > > 3) Although there were more AEs in the older age groups, therate of > > > SAEs was the same and treatment drop-outs were the same or less

than > > > the younger age groups. > > > 4) Pts. should not be denied anti-viral therapy based upon agealone.> > > > > > *Poster presents data updated since abstract submission.

> > > > > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> > > R) study was a prospective, multicenter, community and academic-> > > based, open-label, investigator-initiated, US clinical trial that > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > > > or weight-based ribavirin in treatment-naive patients with chronic > > > hepatitis C.> > > - Overall SVR rates were 44% in the weight-based ribavirin arm and > > > 41% in the flat-dose ribavirin arm (P = .020).3> > > - SVR rates in patients with chronic hepatitis C caused byhepatitis > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P > > > =.004).3> > > - Weight-based ribavirin dosing was associated with higher rates of > > > dose reduction for anemia but not with higher rates of > > > discontinuation.3

> > >> > > > > > > > > > > > ---------------------------------> > Everyone is raving about the all-new beta. > >

> > > > > > > > > > > > Jackie> >> > > > > > > Jackie>

[Guest guest]

im finding that out.alot of people tell me im to skinny im 5'9 and 166.im thinking there just used to seeing me soooo big at 240.im still loseing and now cant seem to stop.i get obessed with it and have made efforts to eat some bad stuff,to not keep loseing it so fast.i have many doubts abvout bmi.i got a friend body builder shows hes 60 pounds over but less then 10% body fat.hes big but not in fat so im sure shes rightAlly <4thMoon@...> wrote: , 115 sounds seriously underweight. You shouldn't go

by BMI anyway as it doesn't take muscle mass into account whatsoever. I am 5'1" and weigh around 132 and am NOT overweight because muscle weighs much more then fat. If I go by BMI then it says that I am very overweight. I got down to 122 at one time and ended up seriously risking my health because of being underweight, yes 122 at 5'1" is way underweight for me. The best thing to do is have your body fat % checked then determine your weight based on that. Ally On 11/10/06, <marvindamartian05 > wrote: I am 5' 2" and about 155 lbs. I was 165 when I was diagnosed, and mydetoxing and improved diet, not to mention stopping drinking bothalcohol

and soda the minute I learned I had Hep C, got about 10 lbsoff in the last 2 months. My pants are hanging off me now. My goal isto be down to 140 when I start tx. But my acupuncturist says I shouldbe about 115, but I will look emaciated at that weight - I know thisfrom past experience. I really do have "big bones" and they will stick out at 115...maybe this is a good thing?Whatever I have to do to increase my odds, I will do!> > >> > > PegIntron/RBV Effective for >65 Year Olds> > > > > > Reported by Jules Levin > > > AASLD, Oct 27-31, 2006, Boston, MA> > > > > > "Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > > > and Well Tolerated in Patients >65 Years Old in Comparison to Other > > > Age Groups: Subanalysis of a Randomized, Controlled Study

(WIN-R > > > Trial)"> > > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. Pound,10 J. > > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > > 1Northwestern University, Chicago, Illinois; 2Weill Medical College > > > of Cornell University, New York, New York; 3Columbia University > > > College of Medicine, New York, New York; 4Baptist Medical Center, > > > Kansas City, Missouri;> > > 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > > > 6Indiana University School of Medicine, Indianapolis, Indiana; > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;8Austin > > > Gastroenterology, PA, Austin, Texas;> > > 9California Pacific Medical Center, San Francisco, California; > >

> 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > > > AUTHOR CONCLUSIONS> > > Patients 18 to 25 years of age had the highest SVR rate (57%) among > > > the 6 age groups.> > > > > > The SVR rate in patients older than 65 years (46%) was similarto the > > > SVR rates observed in younger age groups (41%-57%).> > > > > > Although elderly patients tended to experience more AEs, therate of > > > SAEs was similar in all groups, and the incidence of treatment > > > discontinuation in elderly patients was similar to or less than that > > > of younger patients.> > > > > > Data from this subanalysis of the WIN-R trial strongly suggest that > > > patients should not be denied

antiviral therapy based on age alone. > > > > > > > > > Abstract*> > > Background: Peg interferon (IFN) + ribavirin are the standard ofcare > > > for chronic HCV. There is reluctance to administer anti-viral > > > medications to older populations due to a fear of side effects and > > > possible decreased efficacy. Limited data is available on pts. age > > > >65 due to ineligibility for clinical trials. The role of age in > > > determining response to IFN-based antiviral therapy for chronic HCV > > > has not been clearly defined.> > > > > > Aim: To determine if age is an independent predictor of sustained > > > virological response (SVR) or medication tolerability within a > > > randomized, controlled clinical trial of treatment-naive pts. with > > > HCV. Patient age grps

studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > > > yrs., n=55.> > > > > > Methods: A retrospective review of the multi-center WIN-R trial > > > database was undertaken. Pts. were randomized to receive PEG IFN 2b > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of therapy > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks oftherapy. > > > 4913 pts. received at least 1 dose of medication and areincluded in > > > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > > > pts. Were enrolled as protocol exceptions. Logistic regression > > > analyses of SVR comparing two age categories were performed. The > >

> potential influence of demographic variables on SVR was evaluated > > > using the chi square test (two-way frequency table).> > > > > > Results: > > > The overall SVR was 44%. > > > > > > SVR rates for the grps were: > > > 18-25 yrs. = 57%, > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > > 46-55 yrs. = 42%, > > > 56-65 yrs. = 40% (p= 0.01 vs 18-25) and for > > > >65 yrs. SVR = 45%.> > > > > > There was no difference in SVR in any other pt. age grps including > > > pts. age >65 yrs. > > > > > > There were no differences in SAEs between all age groups. Pts.age 26-> > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those inthe 56-> > > 65 yrs. and the >65 yrs. age

groups. > > > > > > Treatment discontinuations were significantly higher among the26-35 > > > yrs. group when compared to two groups but there was nodifference in > > > the treatment discontinuations in the >65 yrs. group compared with > > > any other.> > > > > > Conclusions: > > > 1) Adults age 18-25 yrs. had significantly increased chances of > > > obtaining SVR than most other age groups. > > > 2) Pts. >65 had similar SVR to all other age groups. > > > 3) Although there were more AEs in the older age groups, therate of > > > SAEs was the same and treatment drop-outs were the same or less than > > > the younger age groups. > > > 4) Pts. should not be denied anti-viral therapy based upon agealone.> > > > > > *Poster presents data updated

since abstract submission. > > > > > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> > > R) study was a prospective, multicenter, community and academic-> > > based, open-label, investigator-initiated, US clinical trial that > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > > > or weight-based ribavirin in treatment-naive patients with chronic > > > hepatitis C.> > > - Overall SVR rates were 44% in the weight-based ribavirin arm and > > > 41% in the flat-dose ribavirin arm (P = .020).3> > > - SVR rates in patients with chronic hepatitis C caused byhepatitis > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P > > > =.004).3> > > - Weight-based ribavirin dosing was associated with higher rates of > > >

dose reduction for anemia but not with higher rates of > > > discontinuation.3 > > >> > > > > > > > > > > > ---------------------------------> > Everyone is raving about the all-new beta. > > > > > > > > > > > > > > Jackie> >> > > > > > > Jackie> Tim Parsons knoxville,tn 37931 865-588-2465 x107 work

www.knoxville1.com

Cheap Talk? Check out Messenger's low PC-to-Phone call rates.

[Guest guest]

Oh well...just me trying to change the world again!

> > > > >

> > > > > PegIntron/RBV Effective for >65 Year Olds

> > > > >

> > > > > Reported by Jules Levin

> > > > > AASLD, Oct 27-31, 2006, Boston, MA

> > > > >

> > > > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally

> > > Efficacious

> > > > > and Well Tolerated in Patients >65 Years Old in Comparison

to

> > > Other

> > > > > Age Groups: Subanalysis of a Randomized, Controlled Study

> > > (WIN-R

> > > > > Trial)â?

> > > > >

> > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4

N.

> > > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> > > Pound,10 J.

> > > > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > > > 1Northwestern University, Chicago, Illinois; 2Weill Medical

> > > College

> > > > > of Cornell University, New York, New York; 3Columbia

> > > University

> > > > > College of Medicine, New York, New York; 4Baptist Medical

> > > Center,

> > > > > Kansas City, Missouri;

> > > > > 5Beth Israel Deaconness Medical Center, Boston,

> > > Massachusetts;

> > > > > 6Indiana University School of Medicine, Indianapolis,

> > > Indiana;

> > > > > 7Atlantic Gastroenterology, Egg Harbor Township, New

Jersey;

> > > 8Austin

> > > > > Gastroenterology, PA, Austin, Texas;

> > > > > 9California Pacific Medical Center, San Francisco,

> > > California;

> > > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis,

Indiana;

> > > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> > > > >

> > > > > AUTHOR CONCLUSIONS

> > > > > Patients 18 to 25 years of age had the highest SVR rate

(57%)

> > > among

> > > > > the 6 age groups.

> > > > >

> > > > > The SVR rate in patients older than 65 years (46%) was

> > > similar to the

> > > > > SVR rates observed in younger age groups (41%-57%).

> > > > >

> > > > > Although elderly patients tended to experience more AEs,

the

> > > rate of

> > > > > SAEs was similar in all groups, and the incidence of

> > > treatment

> > > > > discontinuation in elderly patients was similar to or less

> > > than that

> > > > > of younger patients.

> > > > >

> > > > > Data from this subanalysis of the WIN-R trial strongly

> > > suggest that

> > > > > patients should not be denied antiviral therapy based on

age

> > > alone.

> > > > >

> > > > >

> > > > > Abstract*

> > > > > Background: Peg interferon (IFN) + ribavirin are the

standard

> > > of care

> > > > > for chronic HCV. There is reluctance to administer anti-

viral

> > > > > medications to older populations due to a fear of side

> > > effects and

> > > > > possible decreased efficacy. Limited data is available on

> > > pts. age

> > > > > >65 due to ineligibility for clinical trials. The role of

age

> > > in

> > > > > determining response to IFN-based antiviral therapy for

> > > chronic HCV

> > > > > has not been clearly defined.

> > > > >

> > > > > Aim: To determine if age is an independent predictor of

> > > sustained

> > > > > virological response (SVR) or medication tolerability

within

> > > a

> > > > > randomized, controlled clinical trial of treatment-naive

pts.

> > > with

> > > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35

yrs.,

> > > n=350;

> > > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

> > > and >65

> > > > > yrs., n=55.

> > > > >

> > > > > Methods: A retrospective review of the multi-center WIN-R

> > > trial

> > > > > database was undertaken. Pts. were randomized to receive

PEG

> > > IFN 2b

> > > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin

800mg-

> > > 1400

> > > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks

of

> > > therapy

> > > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks

of

> > > therapy.

> > > > > 4913 pts. received at least 1 dose of medication and are

> > > included in

> > > > > this analysis. Although pts. age >65 yrs. were ineligible,

55

> > > such

> > > > > pts. Were enrolled as protocol exceptions. Logistic

> > > regression

> > > > > analyses of SVR comparing two age categories were

performed.

> > > The

> > > > > potential influence of demographic variables on SVR was

> > > evaluated

> > > > > using the chi square test (two-way frequency table).

> > > > >

> > > > > Results:

> > > > > The overall SVR was 44%.

> > > > >

> > > > > SVR rates for the grps were:

> > > > > 18-25 yrs. = 57%,

> > > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > > > 46-55 yrs. = 42%,

> > > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for

> > > > > >65 yrs. SVR = 45%.

> > > > >

> > > > > There was no difference in SVR in any other pt. age grps

> > > including

> > > > > pts. age >65 yrs.

> > > > >

> > > > > There were no differences in SAEs between all age groups.

> > > Pts. age 26-

> > > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those

> > > in the 56-

> > > > > 65 yrs. and the >65 yrs. age groups.

> > > > >

> > > > > Treatment discontinuations were significantly higher among

> > > the 26-35

> > > > > yrs. group when compared to two groups but there was no

> > > difference in

> > > > > the treatment discontinuations in the >65 yrs. group

compared

> > > with

> > > > > any other.

> > > > >

> > > > > Conclusions:

> > > > > 1) Adults age 18-25 yrs. had significantly increased

chances

> > > of

> > > > > obtaining SVR than most other age groups.

> > > > > 2) Pts. >65 had similar SVR to all other age groups.

> > > > > 3) Although there were more AEs in the older age groups,

the

> > > rate of

> > > > > SAEs was the same and treatment drop-outs were the same or

> > > less than

> > > > > the younger age groups.

> > > > > 4) Pts. should not be denied anti-viral therapy based upon

> > > age alone.

> > > > >

> > > > > *Poster presents data updated since abstract submission.

> > > > >

> > > > >

> > > > > The Weight-Based Dosing of Peginterferon alfa-2b and

> > > Ribavirin (WIN-

> > > > > R) study was a prospective, multicenter, community and

> > > academic-

> > > > > based, open-label, investigator-initiated, US clinical

trial

> > > that

> > > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

> > > flat-dose

> > > > > or weight-based ribavirin in treatment-naive patients with

> > > chronic

> > > > > hepatitis C.

> > > > > - Overall SVR rates were 44% in the weight-based ribavirin

> > > arm and

> > > > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > > > - SVR rates in patients with chronic hepatitis C caused by

> > > hepatitis

> > > > > C virus (HCV) genotype 1 (G1) were 34% and 29%,

respectively

> > > (P

> > > > > =.004).3

> > > > > - Weight-based ribavirin dosing was associated with higher

> > > rates of

> > > > > dose reduction for anemia but not with higher rates of

> > > > > discontinuation.3

> > > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > ----------------------------------------------------------

> > > ----------

> > > > Everyone is raving about the all-new beta.

> > > >

> > >

> > >

> > >

> > >

> > >

> > >

> > > ---------------------------------

> > > Everyone is raving about the all-new beta.

> > >

> >

> >

> >

> >

> >

> >

> > Jackie

> >

>

>

>

>

>

>

> Jackie

>

[Guest guest]

Ok!

> > > >

> > > > PegIntron/RBV Effective for >65 Year Olds

> > > >

> > > > Reported by Jules Levin

> > > > AASLD, Oct 27-31, 2006, Boston, MA

> > > >

> > > > “Pegylated Interferon alfa-2b + Ribavirin Is Equally

Efficacious

> > > > and Well Tolerated in Patients >65 Years Old in Comparison to

Other

> > > > Age Groups: Subanalysis of a Randomized, Controlled Study

(WIN-R

> > > > Trial)â€

> > > >

> > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N.

> > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> Pound,10 J.

> > > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > > 1Northwestern University, Chicago, Illinois; 2Weill Medical

College

> > > > of Cornell University, New York, New York; 3Columbia

University

> > > > College of Medicine, New York, New York; 4Baptist Medical

Center,

> > > > Kansas City, Missouri;

> > > > 5Beth Israel Deaconness Medical Center, Boston,

Massachusetts;

> > > > 6Indiana University School of Medicine, Indianapolis,

Indiana;

> > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;

> 8Austin

> > > > Gastroenterology, PA, Austin, Texas;

> > > > 9California Pacific Medical Center, San Francisco,

California;

> > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana;

> > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> > > >

> > > > AUTHOR CONCLUSIONS

> > > > Patients 18 to 25 years of age had the highest SVR rate (57%)

among

> > > > the 6 age groups.

> > > >

> > > > The SVR rate in patients older than 65 years (46%) was similar

> to the

> > > > SVR rates observed in younger age groups (41%-57%).

> > > >

> > > > Although elderly patients tended to experience more AEs, the

> rate of

> > > > SAEs was similar in all groups, and the incidence of

treatment

> > > > discontinuation in elderly patients was similar to or less

than

> that

> > > > of younger patients.

> > > >

> > > > Data from this subanalysis of the WIN-R trial strongly

suggest that

> > > > patients should not be denied antiviral therapy based on age

alone.

> > > >

> > > >

> > > > Abstract*

> > > > Background: Peg interferon (IFN) + ribavirin are the standard

of

> care

> > > > for chronic HCV. There is reluctance to administer anti-viral

> > > > medications to older populations due to a fear of side

effects and

> > > > possible decreased efficacy. Limited data is available on

pts. age

> > > > >65 due to ineligibility for clinical trials. The role of age

in

> > > > determining response to IFN-based antiviral therapy for

chronic HCV

> > > > has not been clearly defined.

> > > >

> > > > Aim: To determine if age is an independent predictor of

sustained

> > > > virological response (SVR) or medication tolerability within

a

> > > > randomized, controlled clinical trial of treatment-naive pts.

with

> > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs.,

n=350;

> > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

and >65

> > > > yrs., n=55.

> > > >

> > > > Methods: A retrospective review of the multi-center WIN-R

trial

> > > > database was undertaken. Pts. were randomized to receive PEG

IFN 2b

> > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-

1400

> > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of

> therapy

> > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of

> therapy.

> > > > 4913 pts. received at least 1 dose of medication and are

> included in

> > > > this analysis. Although pts. age >65 yrs. were ineligible, 55

such

> > > > pts. Were enrolled as protocol exceptions. Logistic

regression

> > > > analyses of SVR comparing two age categories were performed.

The

> > > > potential influence of demographic variables on SVR was

evaluated

> > > > using the chi square test (two-way frequency table).

> > > >

> > > > Results:

> > > > The overall SVR was 44%.

> > > >

> > > > SVR rates for the grps were:

> > > > 18-25 yrs. = 57%,

> > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > > 46-55 yrs. = 42%,

> > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for

> > > > >65 yrs. SVR = 45%.

> > > >

> > > > There was no difference in SVR in any other pt. age grps

including

> > > > pts. age >65 yrs.

> > > >

> > > > There were no differences in SAEs between all age groups. Pts.

> age 26-

> > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in

> the 56-

> > > > 65 yrs. and the >65 yrs. age groups.

> > > >

> > > > Treatment discontinuations were significantly higher among the

> 26-35

> > > > yrs. group when compared to two groups but there was no

> difference in

> > > > the treatment discontinuations in the >65 yrs. group compared

with

> > > > any other.

> > > >

> > > > Conclusions:

> > > > 1) Adults age 18-25 yrs. had significantly increased chances

of

> > > > obtaining SVR than most other age groups.

> > > > 2) Pts. >65 had similar SVR to all other age groups.

> > > > 3) Although there were more AEs in the older age groups, the

> rate of

> > > > SAEs was the same and treatment drop-outs were the same or

less

> than

> > > > the younger age groups.

> > > > 4) Pts. should not be denied anti-viral therapy based upon age

> alone.

> > > >

> > > > *Poster presents data updated since abstract submission.

> > > >

> > > >

> > > > The Weight-Based Dosing of Peginterferon alfa-2b and

Ribavirin (WIN-

> > > > R) study was a prospective, multicenter, community and

academic-

> > > > based, open-label, investigator-initiated, US clinical trial

that

> > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

flat-dose

> > > > or weight-based ribavirin in treatment-naive patients with

chronic

> > > > hepatitis C.

> > > > - Overall SVR rates were 44% in the weight-based ribavirin

arm and

> > > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > > - SVR rates in patients with chronic hepatitis C caused by

> hepatitis

> > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively

(P

> > > > =.004).3

> > > > - Weight-based ribavirin dosing was associated with higher

rates of

> > > > dose reduction for anemia but not with higher rates of

> > > > discontinuation.3

> > > >

> > >

> > >

> > >

> > >

> > >

> > > ---------------------------------

> > > Everyone is raving about the all-new beta.

> > >

> > >

> > >

> > >

> > >

> > >

> > > Jackie

> > >

> >

> >

> >

> >

> >

> >

> > Jackie

> >

>

>

>

>

>

>

> Jackie

>

[Guest guest]

Thank you Ally! this is what I thought! I am somewhat muscular,

sturdily built and all of that. I will take your advice! You make

more sense than the TCM practioner and the western doc.

> > > > >

> > > > > PegIntron/RBV Effective for >65 Year Olds

> > > > >

> > > > > Reported by Jules Levin

> > > > > AASLD, Oct 27-31, 2006, Boston, MA

> > > > >

> > > > > " Pegylated Interferon alfa-2b + Ribavirin Is Equally

Efficacious

> > > > > and Well Tolerated in Patients >65 Years Old in Comparison

to Other

> > > > > Age Groups: Subanalysis of a Randomized, Controlled Study

(WIN-R

> > > > > Trial) "

> > > > >

> > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4

N.

> > > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> > Pound,10 J.

> > > > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > > > 1Northwestern University, Chicago, Illinois; 2Weill Medical

College

> > > > > of Cornell University, New York, New York; 3Columbia

University

> > > > > College of Medicine, New York, New York; 4Baptist Medical

Center,

> > > > > Kansas City, Missouri;

> > > > > 5Beth Israel Deaconness Medical Center, Boston,

Massachusetts;

> > > > > 6Indiana University School of Medicine, Indianapolis,

Indiana;

> > > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;

> > 8Austin

> > > > > Gastroenterology, PA, Austin, Texas;

> > > > > 9California Pacific Medical Center, San Francisco,

California;

> > > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis,

Indiana;

> > > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> > > > >

> > > > > AUTHOR CONCLUSIONS

> > > > > Patients 18 to 25 years of age had the highest SVR rate

(57%) among

> > > > > the 6 age groups.

> > > > >

> > > > > The SVR rate in patients older than 65 years (46%) was

similar

> > to the

> > > > > SVR rates observed in younger age groups (41%-57%).

> > > > >

> > > > > Although elderly patients tended to experience more AEs, the

> > rate of

> > > > > SAEs was similar in all groups, and the incidence of

treatment

> > > > > discontinuation in elderly patients was similar to or less

than

> > that

> > > > > of younger patients.

> > > > >

> > > > > Data from this subanalysis of the WIN-R trial strongly

suggest that

> > > > > patients should not be denied antiviral therapy based on

age alone.

> > > > >

> > > > >

> > > > > Abstract*

> > > > > Background: Peg interferon (IFN) + ribavirin are the

standard of

> > care

> > > > > for chronic HCV. There is reluctance to administer anti-

viral

> > > > > medications to older populations due to a fear of side

effects and

> > > > > possible decreased efficacy. Limited data is available on

pts. age

> > > > > >65 due to ineligibility for clinical trials. The role of

age in

> > > > > determining response to IFN-based antiviral therapy for

chronic HCV

> > > > > has not been clearly defined.

> > > > >

> > > > > Aim: To determine if age is an independent predictor of

sustained

> > > > > virological response (SVR) or medication tolerability

within a

> > > > > randomized, controlled clinical trial of treatment-naive

pts. with

> > > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35

yrs., n=350;

> > > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

and >65

> > > > > yrs., n=55.

> > > > >

> > > > > Methods: A retrospective review of the multi-center WIN-R

trial

> > > > > database was undertaken. Pts. were randomized to receive

PEG IFN 2b

> > > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin

800mg-1400

> > > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks

of

> > therapy

> > > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of

> > therapy.

> > > > > 4913 pts. received at least 1 dose of medication and are

> > included in

> > > > > this analysis. Although pts. age >65 yrs. were ineligible,

55 such

> > > > > pts. Were enrolled as protocol exceptions. Logistic

regression

> > > > > analyses of SVR comparing two age categories were

performed. The

> > > > > potential influence of demographic variables on SVR was

evaluated

> > > > > using the chi square test (two-way frequency table).

> > > > >

> > > > > Results:

> > > > > The overall SVR was 44%.

> > > > >

> > > > > SVR rates for the grps were:

> > > > > 18-25 yrs. = 57%,

> > > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > > > 46-55 yrs. = 42%,

> > > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for

> > > > > >65 yrs. SVR = 45%.

> > > > >

> > > > > There was no difference in SVR in any other pt. age grps

including

> > > > > pts. age >65 yrs.

> > > > >

> > > > > There were no differences in SAEs between all age groups.

Pts.

> > age 26-

> > > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those

in

> > the 56-

> > > > > 65 yrs. and the >65 yrs. age groups.

> > > > >

> > > > > Treatment discontinuations were significantly higher among

the

> > 26-35

> > > > > yrs. group when compared to two groups but there was no

> > difference in

> > > > > the treatment discontinuations in the >65 yrs. group

compared with

> > > > > any other.

> > > > >

> > > > > Conclusions:

> > > > > 1) Adults age 18-25 yrs. had significantly increased

chances of

> > > > > obtaining SVR than most other age groups.

> > > > > 2) Pts. >65 had similar SVR to all other age groups.

> > > > > 3) Although there were more AEs in the older age groups, the

> > rate of

> > > > > SAEs was the same and treatment drop-outs were the same or

less

> > than

> > > > > the younger age groups.

> > > > > 4) Pts. should not be denied anti-viral therapy based upon

age

> > alone.

> > > > >

> > > > > *Poster presents data updated since abstract submission.

> > > > >

> > > > >

> > > > > The Weight-Based Dosing of Peginterferon alfa-2b and

Ribavirin (WIN-

> > > > > R) study was a prospective, multicenter, community and

academic-

> > > > > based, open-label, investigator-initiated, US clinical

trial that

> > > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

flat-dose

> > > > > or weight-based ribavirin in treatment-naive patients with

chronic

> > > > > hepatitis C.

> > > > > - Overall SVR rates were 44% in the weight-based ribavirin

arm and

> > > > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > > > - SVR rates in patients with chronic hepatitis C caused by

> > hepatitis

> > > > > C virus (HCV) genotype 1 (G1) were 34% and 29%,

respectively (P

> > > > > =.004).3

> > > > > - Weight-based ribavirin dosing was associated with higher

rates of

> > > > > dose reduction for anemia but not with higher rates of

> > > > > discontinuation.3

> > > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > ---------------------------------

> > > > Everyone is raving about the all-new beta.

> > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > Jackie

> > > >

> > >

> > >

> > >

> > >

> > >

> > >

> > > Jackie

> > >

> >

> >

> >

>

[Guest guest]

Tim, 5'9 " and 166 does sound a bit underweight to me, but not

terribly. I wouldn't lose anymore weight though - but don't eat junk

either!

> > > >

> > > > PegIntron/RBV Effective for >65 Year Olds

> > > >

> > > > Reported by Jules Levin

> > > > AASLD, Oct 27-31, 2006, Boston, MA

> > > >

> > > > " Pegylated Interferon alfa-2b + Ribavirin Is Equally

Efficacious

> > > > and Well Tolerated in Patients >65 Years Old in Comparison to

Other

> > > > Age Groups: Subanalysis of a Randomized, Controlled Study

(WIN-R

> > > > Trial) "

> > > >

> > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N.

> > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> Pound,10 J.

> > > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > > 1Northwestern University, Chicago, Illinois; 2Weill Medical

College

> > > > of Cornell University, New York, New York; 3Columbia

University

> > > > College of Medicine, New York, New York; 4Baptist Medical

Center,

> > > > Kansas City, Missouri;

> > > > 5Beth Israel Deaconness Medical Center, Boston,

Massachusetts;

> > > > 6Indiana University School of Medicine, Indianapolis,

Indiana;

> > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey;

> 8Austin

> > > > Gastroenterology, PA, Austin, Texas;

> > > > 9California Pacific Medical Center, San Francisco,

California;

> > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana;

> > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey

> > > >

> > > > AUTHOR CONCLUSIONS

> > > > Patients 18 to 25 years of age had the highest SVR rate (57%)

among

> > > > the 6 age groups.

> > > >

> > > > The SVR rate in patients older than 65 years (46%) was similar

> to the

> > > > SVR rates observed in younger age groups (41%-57%).

> > > >

> > > > Although elderly patients tended to experience more AEs, the

> rate of

> > > > SAEs was similar in all groups, and the incidence of

treatment

> > > > discontinuation in elderly patients was similar to or less

than

> that

> > > > of younger patients.

> > > >

> > > > Data from this subanalysis of the WIN-R trial strongly

suggest that

> > > > patients should not be denied antiviral therapy based on age

alone.

> > > >

> > > >

> > > > Abstract*

> > > > Background: Peg interferon (IFN) + ribavirin are the standard

of

> care

> > > > for chronic HCV. There is reluctance to administer anti-viral

> > > > medications to older populations due to a fear of side

effects and

> > > > possible decreased efficacy. Limited data is available on

pts. age

> > > > >65 due to ineligibility for clinical trials. The role of age

in

> > > > determining response to IFN-based antiviral therapy for

chronic HCV

> > > > has not been clearly defined.

> > > >

> > > > Aim: To determine if age is an independent predictor of

sustained

> > > > virological response (SVR) or medication tolerability within

a

> > > > randomized, controlled clinical trial of treatment-naive pts.

with

> > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs.,

n=350;

> > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

and >65

> > > > yrs., n=55.

> > > >

> > > > Methods: A retrospective review of the multi-center WIN-R

trial

> > > > database was undertaken. Pts. were randomized to receive PEG

IFN 2b

> > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-

1400

> > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of

> therapy

> > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of

> therapy.

> > > > 4913 pts. received at least 1 dose of medication and are

> included in

> > > > this analysis. Although pts. age >65 yrs. were ineligible, 55

such

> > > > pts. Were enrolled as protocol exceptions. Logistic

regression

> > > > analyses of SVR comparing two age categories were performed.

The

> > > > potential influence of demographic variables on SVR was

evaluated

> > > > using the chi square test (two-way frequency table).

> > > >

> > > > Results:

> > > > The overall SVR was 44%.

> > > >

> > > > SVR rates for the grps were:

> > > > 18-25 yrs. = 57%,

> > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > > 46-55 yrs. = 42%,

> > > > 56-65 yrs. = 40% (p= 0.01 vs 18-25) and for

> > > > >65 yrs. SVR = 45%.

> > > >

> > > > There was no difference in SVR in any other pt. age grps

including

> > > > pts. age >65 yrs.

> > > >

> > > > There were no differences in SAEs between all age groups. Pts.

> age 26-

> > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in

> the 56-

> > > > 65 yrs. and the >65 yrs. age groups.

> > > >

> > > > Treatment discontinuations were significantly higher among the

> 26-35

> > > > yrs. group when compared to two groups but there was no

> difference in

> > > > the treatment discontinuations in the >65 yrs. group compared

with

> > > > any other.

> > > >

> > > > Conclusions:

> > > > 1) Adults age 18-25 yrs. had significantly increased chances

of

> > > > obtaining SVR than most other age groups.

> > > > 2) Pts. >65 had similar SVR to all other age groups.

> > > > 3) Although there were more AEs in the older age groups, the

> rate of

> > > > SAEs was the same and treatment drop-outs were the same or

less

> than

> > > > the younger age groups.

> > > > 4) Pts. should not be denied anti-viral therapy based upon age

> alone.

> > > >

> > > > *Poster presents data updated since abstract submission.

> > > >

> > > >

> > > > The Weight-Based Dosing of Peginterferon alfa-2b and

Ribavirin (WIN-

> > > > R) study was a prospective, multicenter, community and

academic-

> > > > based, open-label, investigator-initiated, US clinical trial

that

> > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

flat-dose

> > > > or weight-based ribavirin in treatment-naive patients with

chronic

> > > > hepatitis C.

> > > > - Overall SVR rates were 44% in the weight-based ribavirin

arm and

> > > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > > - SVR rates in patients with chronic hepatitis C caused by

> hepatitis

> > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively

(P

> > > > =.004).3

> > > > - Weight-based ribavirin dosing was associated with higher

rates of

> > > > dose reduction for anemia but not with higher rates of

> > > > discontinuation.3

> > > >

> > >

> > >

> > >

> > >

> > >

> > > ---------------------------------

> > > Everyone is raving about the all-new beta.

> > >

> > >

> > >

> > >

> > >

> > >

> > > Jackie

> > >

> >

> >

> >

> >

> >

> >

> > Jackie

> >

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

> Tim Parsons

>

> knoxville,tn 37931

>

> 865-588-2465 x107 work

>

>

> www.knoxville1.com

>

>

>

> ---------------------------------

> Cheap Talk? Check out Messenger's low PC-to-Phone call rates.

>

[Guest guest]

> > > > >

> > > > > PegIntron/RBV Effective for >65 Year Olds

> > > > >

> > > > > Reported by Jules Levin

> > > > > AASLD, Oct 27-31, 2006, Boston, MA

> > > > >

> > > > > " Pegylated Interferon alfa-2b + Ribavirin Is Equally

> Efficacious

> > > > > and Well Tolerated in Patients >65 Years Old in Comparison

to

> Other

> > > > > Age Groups: Subanalysis of a Randomized, Controlled Study

> (WIN-R

> > > > > Trial) "

> > > > >

> > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4

N.

> > > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> > Pound,10 J.

> > > > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > > > 1Northwestern University, Chicago, Illinois; 2Weill

Medical

> College

> > > > > of Cornell University, New York, New York; 3Columbia

> University

> > > > > College of Medicine, New York, New York; 4Baptist Medical

> Center,

> > > > > Kansas City, Missouri;

> > > > > 5Beth Israel Deaconness Medical Center, Boston,

> Massachusetts;

> > > > > 6Indiana University School of Medicine, Indianapolis,

> Indiana;

> > > > > 7Atlantic Gastroenterology, Egg Harbor Township, New

Jersey;

> > 8Austin

> > > > > Gastroenterology, PA, Austin, Texas;

> > > > > 9California Pacific Medical Center, San Francisco,

> California;

> > > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis,

Indiana;

> > > > > 11Schering-Plough Research Institute, Kenilworth, New

Jersey

> > > > >

> > > > > AUTHOR CONCLUSIONS

> > > > > Patients 18 to 25 years of age had the highest SVR rate

(57%)

> among

> > > > > the 6 age groups.

> > > > >

> > > > > The SVR rate in patients older than 65 years (46%) was

similar

> > to the

> > > > > SVR rates observed in younger age groups (41%-57%).

> > > > >

> > > > > Although elderly patients tended to experience more AEs,

the

> > rate of

> > > > > SAEs was similar in all groups, and the incidence of

> treatment

> > > > > discontinuation in elderly patients was similar to or less

> than

> > that

> > > > > of younger patients.

> > > > >

> > > > > Data from this subanalysis of the WIN-R trial strongly

> suggest that

> > > > > patients should not be denied antiviral therapy based on

age

> alone.

> > > > >

> > > > >

> > > > > Abstract*

> > > > > Background: Peg interferon (IFN) + ribavirin are the

standard

> of

> > care

> > > > > for chronic HCV. There is reluctance to administer anti-

viral

> > > > > medications to older populations due to a fear of side

> effects and

> > > > > possible decreased efficacy. Limited data is available on

> pts. age

> > > > > >65 due to ineligibility for clinical trials. The role of

age

> in

> > > > > determining response to IFN-based antiviral therapy for

> chronic HCV

> > > > > has not been clearly defined.

> > > > >

> > > > > Aim: To determine if age is an independent predictor of

> sustained

> > > > > virological response (SVR) or medication tolerability

within

> a

> > > > > randomized, controlled clinical trial of treatment-naive

pts.

> with

> > > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35

yrs.,

> n=350;

> > > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

> and >65

> > > > > yrs., n=55.

> > > > >

> > > > > Methods: A retrospective review of the multi-center WIN-R

> trial

> > > > > database was undertaken. Pts. were randomized to receive

PEG

> IFN 2b

> > > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin

800mg-

> 1400

> > > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks

of

> > therapy

> > > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks

of

> > therapy.

> > > > > 4913 pts. received at least 1 dose of medication and are

> > included in

> > > > > this analysis. Although pts. age >65 yrs. were ineligible,

55

> such

> > > > > pts. Were enrolled as protocol exceptions. Logistic

> regression

> > > > > analyses of SVR comparing two age categories were

performed.

> The

> > > > > potential influence of demographic variables on SVR was

> evaluated

> > > > > using the chi square test (two-way frequency table).

> > > > >

> > > > > Results:

> > > > > The overall SVR was 44%.

> > > > >

> > > > > SVR rates for the grps were:

> > > > > 18-25 yrs. = 57%,

> > > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > > > 46-55 yrs. = 42%,

> > > > > 56-65 yrs. = 40% (p= 0.01 vs 18-25) and for

> > > > > >65 yrs. SVR = 45%.

> > > > >

> > > > > There was no difference in SVR in any other pt. age grps

> including

> > > > > pts. age >65 yrs.

> > > > >

> > > > > There were no differences in SAEs between all age groups.

Pts.

> > age 26-

> > > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than

those in

> > the 56-

> > > > > 65 yrs. and the >65 yrs. age groups.

> > > > >

> > > > > Treatment discontinuations were significantly higher among

the

> > 26-35

> > > > > yrs. group when compared to two groups but there was no

> > difference in

> > > > > the treatment discontinuations in the >65 yrs. group

compared

> with

> > > > > any other.

> > > > >

> > > > > Conclusions:

> > > > > 1) Adults age 18-25 yrs. had significantly increased

chances

> of

> > > > > obtaining SVR than most other age groups.

> > > > > 2) Pts. >65 had similar SVR to all other age groups.

> > > > > 3) Although there were more AEs in the older age groups,

the

> > rate of

> > > > > SAEs was the same and treatment drop-outs were the same or

> less

> > than

> > > > > the younger age groups.

> > > > > 4) Pts. should not be denied anti-viral therapy based upon

age

> > alone.

> > > > >

> > > > > *Poster presents data updated since abstract submission.

> > > > >

> > > > >

> > > > > The Weight-Based Dosing of Peginterferon alfa-2b and

> Ribavirin (WIN-

> > > > > R) study was a prospective, multicenter, community and

> academic-

> > > > > based, open-label, investigator-initiated, US clinical

trial

> that

> > > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

> flat-dose

> > > > > or weight-based ribavirin in treatment-naive patients with

> chronic

> > > > > hepatitis C.

> > > > > - Overall SVR rates were 44% in the weight-based ribavirin

> arm and

> > > > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > > > - SVR rates in patients with chronic hepatitis C caused by

> > hepatitis

> > > > > C virus (HCV) genotype 1 (G1) were 34% and 29%,

respectively

> (P

> > > > > =.004).3

> > > > > - Weight-based ribavirin dosing was associated with higher

> rates of

> > > > > dose reduction for anemia but not with higher rates of

> > > > > discontinuation.3

> > > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > ---------------------------------

> > > > Everyone is raving about the all-new beta.

> > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > Jackie

> > > >

> > >

> > >

> > >

> > >

> > >

> > >

> > > Jackie

> > >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> > Tim Parsons

> >

> > knoxville,tn 37931

> >

> > 865-588-2465 x107 work

> >

> >

> > www.knoxville1.com

> >

> >

> >

> > ---------------------------------

> > Cheap Talk? Check out Messenger's low PC-to-Phone call

rates.

> >

>

[Guest guest]

> > > > >

> > > > > PegIntron/RBV Effective for >65 Year Olds

> > > > >

> > > > > Reported by Jules Levin

> > > > > AASLD, Oct 27-31, 2006, Boston, MA

> > > > >

> > > > > " Pegylated Interferon alfa-2b + Ribavirin Is Equally

> Efficacious

> > > > > and Well Tolerated in Patients >65 Years Old in Comparison

to

> Other

> > > > > Age Groups: Subanalysis of a Randomized, Controlled Study

> (WIN-R

> > > > > Trial) "

> > > > >

> > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4

N.

> > > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D.

> > Pound,10 J.

> > > > > Harvey,11 L. H. Griffel,11 C. A. Brass11

> > > > > 1Northwestern University, Chicago, Illinois; 2Weill

Medical

> College

> > > > > of Cornell University, New York, New York; 3Columbia

> University

> > > > > College of Medicine, New York, New York; 4Baptist Medical

> Center,

> > > > > Kansas City, Missouri;

> > > > > 5Beth Israel Deaconness Medical Center, Boston,

> Massachusetts;

> > > > > 6Indiana University School of Medicine, Indianapolis,

> Indiana;

> > > > > 7Atlantic Gastroenterology, Egg Harbor Township, New

Jersey;

> > 8Austin

> > > > > Gastroenterology, PA, Austin, Texas;

> > > > > 9California Pacific Medical Center, San Francisco,

> California;

> > > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis,

Indiana;

> > > > > 11Schering-Plough Research Institute, Kenilworth, New

Jersey

> > > > >

> > > > > AUTHOR CONCLUSIONS

> > > > > Patients 18 to 25 years of age had the highest SVR rate

(57%)

> among

> > > > > the 6 age groups.

> > > > >

> > > > > The SVR rate in patients older than 65 years (46%) was

similar

> > to the

> > > > > SVR rates observed in younger age groups (41%-57%).

> > > > >

> > > > > Although elderly patients tended to experience more AEs,

the

> > rate of

> > > > > SAEs was similar in all groups, and the incidence of

> treatment

> > > > > discontinuation in elderly patients was similar to or less

> than

> > that

> > > > > of younger patients.

> > > > >

> > > > > Data from this subanalysis of the WIN-R trial strongly

> suggest that

> > > > > patients should not be denied antiviral therapy based on

age

> alone.

> > > > >

> > > > >

> > > > > Abstract*

> > > > > Background: Peg interferon (IFN) + ribavirin are the

standard

> of

> > care

> > > > > for chronic HCV. There is reluctance to administer anti-

viral

> > > > > medications to older populations due to a fear of side

> effects and

> > > > > possible decreased efficacy. Limited data is available on

> pts. age

> > > > > >65 due to ineligibility for clinical trials. The role of

age

> in

> > > > > determining response to IFN-based antiviral therapy for

> chronic HCV

> > > > > has not been clearly defined.

> > > > >

> > > > > Aim: To determine if age is an independent predictor of

> sustained

> > > > > virological response (SVR) or medication tolerability

within

> a

> > > > > randomized, controlled clinical trial of treatment-naive

pts.

> with

> > > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35

yrs.,

> n=350;

> > > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368;

> and >65

> > > > > yrs., n=55.

> > > > >

> > > > > Methods: A retrospective review of the multi-center WIN-R

> trial

> > > > > database was undertaken. Pts. were randomized to receive

PEG

> IFN 2b

> > > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin

800mg-

> 1400

> > > > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks

of

> > therapy

> > > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks

of

> > therapy.

> > > > > 4913 pts. received at least 1 dose of medication and are

> > included in

> > > > > this analysis. Although pts. age >65 yrs. were ineligible,

55

> such

> > > > > pts. Were enrolled as protocol exceptions. Logistic

> regression

> > > > > analyses of SVR comparing two age categories were

performed.

> The

> > > > > potential influence of demographic variables on SVR was

> evaluated

> > > > > using the chi square test (two-way frequency table).

> > > > >

> > > > > Results:

> > > > > The overall SVR was 44%.

> > > > >

> > > > > SVR rates for the grps were:

> > > > > 18-25 yrs. = 57%,

> > > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),

> > > > > 36-45 yrs. = 44% (p=0.03 vs 18-25),

> > > > > 46-55 yrs. = 42%,

> > > > > 56-65 yrs. = 40% (p= 0.01 vs 18-25) and for

> > > > > >65 yrs. SVR = 45%.

> > > > >

> > > > > There was no difference in SVR in any other pt. age grps

> including

> > > > > pts. age >65 yrs.

> > > > >

> > > > > There were no differences in SAEs between all age groups.

Pts.

> > age 26-

> > > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than

those in

> > the 56-

> > > > > 65 yrs. and the >65 yrs. age groups.

> > > > >

> > > > > Treatment discontinuations were significantly higher among

the

> > 26-35

> > > > > yrs. group when compared to two groups but there was no

> > difference in

> > > > > the treatment discontinuations in the >65 yrs. group

compared

> with

> > > > > any other.

> > > > >

> > > > > Conclusions:

> > > > > 1) Adults age 18-25 yrs. had significantly increased

chances

> of

> > > > > obtaining SVR than most other age groups.

> > > > > 2) Pts. >65 had similar SVR to all other age groups.

> > > > > 3) Although there were more AEs in the older age groups,

the

> > rate of

> > > > > SAEs was the same and treatment drop-outs were the same or

> less

> > than

> > > > > the younger age groups.

> > > > > 4) Pts. should not be denied anti-viral therapy based upon

age

> > alone.

> > > > >

> > > > > *Poster presents data updated since abstract submission.

> > > > >

> > > > >

> > > > > The Weight-Based Dosing of Peginterferon alfa-2b and

> Ribavirin (WIN-

> > > > > R) study was a prospective, multicenter, community and

> academic-

> > > > > based, open-label, investigator-initiated, US clinical

trial

> that

> > > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus

> flat-dose

> > > > > or weight-based ribavirin in treatment-naive patients with

> chronic

> > > > > hepatitis C.

> > > > > - Overall SVR rates were 44% in the weight-based ribavirin

> arm and

> > > > > 41% in the flat-dose ribavirin arm (P = .020).3

> > > > > - SVR rates in patients with chronic hepatitis C caused by

> > hepatitis

> > > > > C virus (HCV) genotype 1 (G1) were 34% and 29%,

respectively

> (P

> > > > > =.004).3

> > > > > - Weight-based ribavirin dosing was associated with higher

> rates of

> > > > > dose reduction for anemia but not with higher rates of

> > > > > discontinuation.3

> > > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > ---------------------------------

> > > > Everyone is raving about the all-new beta.

> > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > Jackie

> > > >

> > >

> > >

> > >

> > >

> > >

> > >

> > > Jackie

> > >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> >

> > Tim Parsons

> >

> > knoxville,tn 37931

> >

> > 865-588-2465 x107 work

> >

> >

> > www.knoxville1.com

> >

> >

> >

> > ---------------------------------

> > Cheap Talk? Check out Messenger's low PC-to-Phone call

rates.

> >

>

[Guest guest]

well its a great idea,, too bad they cant make it work! <marvindamartian05@...> wrote: Oh well...just me trying to change the world again!> > > > >> > > > > PegIntron/RBV Effective for >65 Year Olds> > > > > > > > > > Reported by Jules Levin> > > > > AASLD, Oct 27-31, 2006, Boston,

MA> > > > > > > > > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally > > > Efficacious > > > > > and Well Tolerated in Patients >65 Years Old in Comparison to > > > Other > > > > > Age Groups: Subanalysis of a Randomized, Controlled Study > > > (WIN-R > > > > > Trial)â?> > > > > > > > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > > > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. > > > Pound,10 J. > > > > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > > > > 1Northwestern University, Chicago, Illinois; 2Weill Medical > > > College > > > > > of Cornell University, New York, New York; 3Columbia > > > University > > > > >

College of Medicine, New York, New York; 4Baptist Medical > > > Center, > > > > > Kansas City, Missouri;> > > > > 5Beth Israel Deaconness Medical Center, Boston, > > > Massachusetts; > > > > > 6Indiana University School of Medicine, Indianapolis, > > > Indiana; > > > > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; > > > 8Austin > > > > > Gastroenterology, PA, Austin, Texas;> > > > > 9California Pacific Medical Center, San Francisco, > > > California; > > > > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > > > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > > > > > > > AUTHOR CONCLUSIONS> > > > > Patients 18 to 25 years of age had the

highest SVR rate (57%) > > > among > > > > > the 6 age groups.> > > > > > > > > > The SVR rate in patients older than 65 years (46%) was > > > similar to the > > > > > SVR rates observed in younger age groups (41%-57%).> > > > > > > > > > Although elderly patients tended to experience more AEs, the > > > rate of > > > > > SAEs was similar in all groups, and the incidence of > > > treatment > > > > > discontinuation in elderly patients was similar to or less > > > than that > > > > > of younger patients.> > > > > > > > > > Data from this subanalysis of the WIN-R trial strongly > > > suggest that > > > > > patients should not be denied antiviral therapy based on

age > > > alone.> > > > > > > > > > > > > > > Abstract*> > > > > Background: Peg interferon (IFN) + ribavirin are the standard > > > of care > > > > > for chronic HCV. There is reluctance to administer anti-viral > > > > > medications to older populations due to a fear of side > > > effects and > > > > > possible decreased efficacy. Limited data is available on > > > pts. age > > > > > >65 due to ineligibility for clinical trials. The role of age > > > in > > > > > determining response to IFN-based antiviral therapy for > > > chronic HCV > > > > > has not been clearly defined.> > > > > > > > > > Aim: To determine if age is an independent predictor of

> > > sustained > > > > > virological response (SVR) or medication tolerability within > > > a > > > > > randomized, controlled clinical trial of treatment-naive pts. > > > with > > > > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., > > > n=350; > > > > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; > > > and >65 > > > > > yrs., n=55.> > > > > > > > > > Methods: A retrospective review of the multi-center WIN-R > > > trial > > > > > database was undertaken. Pts. were randomized to receive PEG > > > IFN 2b > > > > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-> > > 1400 > > > > > mg/d based on body wt. Pts. with HCV

GT1/4 received 48 wks of > > > therapy > > > > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of > > > therapy. > > > > > 4913 pts. received at least 1 dose of medication and are > > > included in > > > > > this analysis. Although pts. age >65 yrs. were ineligible, 55 > > > such > > > > > pts. Were enrolled as protocol exceptions. Logistic > > > regression > > > > > analyses of SVR comparing two age categories were performed. > > > The > > > > > potential influence of demographic variables on SVR was > > > evaluated > > > > > using the chi square test (two-way frequency table).> > > > > > > > > > Results: > > > > > The overall SVR was 44%. > > > >

> > > > > > SVR rates for the grps were: > > > > > 18-25 yrs. = 57%, > > > > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > > > > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > > > > 46-55 yrs. = 42%, > > > > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > > > > > >65 yrs. SVR = 45%.> > > > > > > > > > There was no difference in SVR in any other pt. age grps > > > including > > > > > pts. age >65 yrs. > > > > > > > > > > There were no differences in SAEs between all age groups. > > > Pts. age 26-> > > > > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those > > > in the 56-> > > > > 65 yrs. and the >65 yrs. age groups. > > > > > > > >

> > Treatment discontinuations were significantly higher among > > > the 26-35 > > > > > yrs. group when compared to two groups but there was no > > > difference in > > > > > the treatment discontinuations in the >65 yrs. group compared > > > with > > > > > any other.> > > > > > > > > > Conclusions: > > > > > 1) Adults age 18-25 yrs. had significantly increased chances > > > of > > > > > obtaining SVR than most other age groups.> > > > > 2) Pts. >65 had similar SVR to all other age groups. > > > > > 3) Although there were more AEs in the older age groups, the > > > rate of > > > > > SAEs was the same and treatment drop-outs were the same or > > > less than > > > > >

the younger age groups. > > > > > 4) Pts. should not be denied anti-viral therapy based upon > > > age alone.> > > > > > > > > > *Poster presents data updated since abstract submission.> > > > > > > > > > > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and > > > Ribavirin (WIN-> > > > > R) study was a prospective, multicenter, community and > > > academic-> > > > > based, open-label, investigator-initiated, US clinical trial > > > that > > > > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus > > > flat-dose > > > > > or weight-based ribavirin in treatment-naive patients with > > > chronic > > > > > hepatitis C.> > > > > - Overall SVR rates

were 44% in the weight-based ribavirin > > > arm and > > > > > 41% in the flat-dose ribavirin arm (P = .020).3> > > > > - SVR rates in patients with chronic hepatitis C caused by > > > hepatitis > > > > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively > > > (P > > > > > =.004).3> > > > > - Weight-based ribavirin dosing was associated with higher > > > rates of > > > > > dose reduction for anemia but not with higher rates of > > > > > discontinuation.3> > > > >> > > > > > > > > > > > > > > > > > > > > > > > > > > > ----------------------------------------------------------> > > ---------->

> > > Everyone is raving about the all-new beta.> > > >> > > > > > > > > > > > > > > > > > > > > ---------------------------------> > > Everyone is raving about the all-new beta.> > >> > > > > > > > > > > > > > Jackie> >> > > > > > > Jackie>Jackie

[Guest guest]

My late husband died at age 52 from liver disease..I dont believe he had hepc just drank too much..he got down to 5'8 120lbs and looked like he was 9 months preggers...he also had emphezima..geri

[Guest guest]

Im sorry Geri, that was an awful thing to have to witness.. us4heavenbound@... wrote: My late husband died at age 52 from liver disease..I dont believe he had hepc just drank too much..he got down to 5'8 120lbs and looked like he was 9 months preggers...he also had emphezima..geri Jackie

[Guest guest]

Yes, it is. I lost my Dad at 17 (he was only 57) to lung cancer, and

then my Mom a few years ago to Emphysema. Lung disease progression is

horrible to witness, and since my Mom suffered for over 10 years, it

can take a toll on everyone in the family including the afflicted. I

took care of Mom for as long as I could, but then I had to admit her

to a nursing home on the orders of the doctor. Nursing homes are a

horror story, in my experience, but that's a subject for a diffferent

support group.

Geri, I am so sorry to hear of your loss. How long ago did you lose

him?

My late husband died at age 52

from liver disease..I dont believe he had hepc just drank too

much..he got down to 5'8 120lbs and looked like he was 9 months

preggers...he also had emphezima..geri

>

>

>

>

>

>

>

>

> Jackie

>

[Guest guest]

You can get most of the research data about both of these meds at www.NATAP.com

Re: Re: Another Question

I have a question, too, one that I've never really had answered,

or else I didn't understand.

As of right now, which drug company has had the better

results with obtaining remission in Genotype "1"s,

Schering-Plough or Roche?

I am still struggling along here.. right along, I'm sure with

a few others...

Thanks in Advance,

Sheena

<marvindamartian05 > wrote:

hat does SAE stand for?

-- In Hepatitis C , "elizabethnv1"<elizabethnv1@...> wrote:>> PegIntron/RBV Effective for >65 Year Olds> > Reported by Jules Levin> AASLD, Oct 27-31, 2006, Boston, MA> > “Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > and Well Tolerated in Patients >65 Years Old in Comparison to Other > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R > Trial)â€> > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. Pound,10 J. > Harvey,11 L. H. Griffel,11 C. A. Brass11> 1Northwestern University, Chicago, Illinois; 2Weill Medical College > of Cornell University, New York, New York; 3Columbia University > College of Medicine, New York, New York; 4Baptist Medical Center, > Kansas City, Missouri;> 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > 6Indiana University School of Medicine, Indianapolis, Indiana; > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; 8Austin > Gastroenterology, PA, Austin, Texas;> 9California Pacific Medical Center, San Francisco, California; > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > AUTHOR CONCLUSIONS> Patients 18 to 25 years of age had the highest SVR rate (57%) among > the 6 age groups.> > The SVR rate in patients older than 65 years (46%) was similar to the > SVR rates observed in younger age groups (41%-57%).> > Although elderly patients tended to experience more AEs, the rate of > SAEs was similar in all groups, and the incidence of treatment > discontinuation in elderly patients was similar to or less than that > of younger patients.> > Data from this subanalysis of the WIN-R trial strongly suggest that > patients should not be denied antiviral therapy based on age alone.> > > Abstract*> Background: Peg interferon (IFN) + ribavirin are the standard of care > for chronic HCV. There is reluctance to administer anti-viral > medications to older populations due to a fear of side effects and > possible decreased efficacy. Limited data is available on pts. age > >65 due to ineligibility for clinical trials. The role of age in > determining response to IFN-based antiviral therapy for chronic HCV > has not been clearly defined.> > Aim: To determine if age is an independent predictor of sustained > virological response (SVR) or medication tolerability within a > randomized, controlled clinical trial of treatment-naive pts. with > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > yrs., n=55.> > Methods: A retrospective review of the multi-center WIN-R trial > database was undertaken. Pts. were randomized to receive PEG IFN 2b > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of therapy > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of therapy. > 4913 pts. received at least 1 dose of medication and are included in > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > pts. Were enrolled as protocol exceptions. Logistic regression > analyses of SVR comparing two age categories were performed. The > potential influence of demographic variables on SVR was evaluated > using the chi square test (two-way frequency table).> > Results: > The overall SVR was 44%. > > SVR rates for the grps were: > 18-25 yrs. = 57%, > 26-35 yrs. = 41% (p=0.02 vs 18-25),> 36-45 yrs. = 44% (p=0.03 vs 18-25), > 46-55 yrs. = 42%, > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > >65 yrs. SVR = 45%.> > There was no difference in SVR in any other pt. age grps including > pts. age >65 yrs. > > There were no differences in SAEs between all age groups. Pts. age 26-> 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in the 56-> 65 yrs. and the >65 yrs. age groups. > > Treatment discontinuations were significantly higher among the 26-35 > yrs. group when compared to two groups but there was no difference in > the treatment discontinuations in the >65 yrs. group compared with > any other.> > Conclusions: > 1) Adults age 18-25 yrs. had significantly increased chances of > obtaining SVR than most other age groups.> 2) Pts. >65 had similar SVR to all other age groups. > 3) Although there were more AEs in the older age groups, the rate of > SAEs was the same and treatment drop-outs were the same or less than > the younger age groups. > 4) Pts. should not be denied anti-viral therapy based upon age alone.> > *Poster presents data updated since abstract submission.> > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> R) study was a prospective, multicenter, community and academic-> based, open-label, investigator-initiated, US clinical trial that > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > or weight-based ribavirin in treatment-naive patients with chronic > hepatitis C.> - Overall SVR rates were 44% in the weight-based ribavirin arm and > 41% in the flat-dose ribavirin arm (P = .020).3> - SVR rates in patients with chronic hepatitis C caused by hepatitis > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P > =.004).3> - Weight-based ribavirin dosing was associated with higher rates of > dose reduction for anemia but not with higher rates of > discontinuation.3>

Everyone is raving about the all-new beta.

Check out the all-new beta - Fire up a more powerful email and get things done faster.

[Guest guest]

Valeant pharmaceuticals

Re: Another Question

Who makes Infergen?> >> > PegIntron/RBV Effective for >65 Year Olds> > > > Reported by Jules Levin> > AASLD, Oct 27-31, 2006, Boston, MA> > > > â?oPegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious > > and Well Tolerated in Patients >65 Years Old in Comparison to Other > > Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R > > Trial)â?> > > > S. L. Flamm,1 I. M. son,2 R. S. Brown,3 B. Freilich,4 N. > > Afdhal,5 P. Kwo,6 J. Santoro,7 S. Becker,8 A. Wakil,9 D. Pound,10 J. > > Harvey,11 L. H. Griffel,11 C. A. Brass11> > 1Northwestern University, Chicago, Illinois; 2Weill Medical College > > of Cornell University, New York, New York; 3Columbia University > > College of Medicine, New York, New York; 4Baptist Medical Center, > > Kansas City, Missouri;> > 5Beth Israel Deaconness Medical Center, Boston, Massachusetts; > > 6Indiana University School of Medicine, Indianapolis, Indiana; > > 7Atlantic Gastroenterology, Egg Harbor Township, New Jersey; 8Austin > > Gastroenterology, PA, Austin, Texas;> > 9California Pacific Medical Center, San Francisco, California; > > 10Indianapolis Gastroenterology, RSCH, Indianapolis, Indiana; > > 11Schering-Plough Research Institute, Kenilworth, New Jersey> > > > AUTHOR CONCLUSIONS> > Patients 18 to 25 years of age had the highest SVR rate (57%) among > > the 6 age groups.> > > > The SVR rate in patients older than 65 years (46%) was similar to the > > SVR rates observed in younger age groups (41%-57%).> > > > Although elderly patients tended to experience more AEs, the rate of > > SAEs was similar in all groups, and the incidence of treatment > > discontinuation in elderly patients was similar to or less than that > > of younger patients.> > > > Data from this subanalysis of the WIN-R trial strongly suggest that > > patients should not be denied antiviral therapy based on age alone.> > > > > > Abstract*> > Background: Peg interferon (IFN) + ribavirin are the standard of care > > for chronic HCV. There is reluctance to administer anti-viral > > medications to older populations due to a fear of side effects and > > possible decreased efficacy. Limited data is available on pts. age > > >65 due to ineligibility for clinical trials. The role of age in > > determining response to IFN-based antiviral therapy for chronic HCV > > has not been clearly defined.> > > > Aim: To determine if age is an independent predictor of sustained > > virological response (SVR) or medication tolerability within a > > randomized, controlled clinical trial of treatment-naive pts. with > > HCV. Patient age grps studied: 18-25 yrs., n=69; 26-35 yrs., n=350; > > 36-45 yrs., n=1866; 46-55 yrs., n=2200; 56-65 yrs., n=368; and >65 > > yrs., n=55.> > > > Methods: A retrospective review of the multi-center WIN-R trial > > database was undertaken. Pts. were randomized to receive PEG IFN 2b > > (1.5 g/kg/wk) + either ribavirin 800 mg/d or ribavirin 800mg-1400 > > mg/d based on body wt. Pts. with HCV GT1/4 received 48 wks of therapy > > while pts with HCV GT 2/3 were randomized to 24 or 48 wks of therapy. > > 4913 pts. received at least 1 dose of medication and are included in > > this analysis. Although pts. age >65 yrs. were ineligible, 55 such > > pts. Were enrolled as protocol exceptions. Logistic regression > > analyses of SVR comparing two age categories were performed. The > > potential influence of demographic variables on SVR was evaluated > > using the chi square test (two-way frequency table).> > > > Results: > > The overall SVR was 44%. > > > > SVR rates for the grps were: > > 18-25 yrs. = 57%, > > 26-35 yrs. = 41% (p=0.02 vs 18-25),> > 36-45 yrs. = 44% (p=0.03 vs 18-25), > > 46-55 yrs. = 42%, > > 56-65 yrs. = 40% (p=0.01 vs 18-25) and for > > >65 yrs. SVR = 45%.> > > > There was no difference in SVR in any other pt. age grps including > > pts. age >65 yrs. > > > > There were no differences in SAEs between all age groups. Pts. age 26-> > 35 yrs., 36-45 yrs. and 46-55 yrs. had fewer AEs than those in the 56-> > 65 yrs. and the >65 yrs. age groups. > > > > Treatment discontinuations were significantly higher among the 26-35 > > yrs. group when compared to two groups but there was no difference in > > the treatment discontinuations in the >65 yrs. group compared with > > any other.> > > > Conclusions: > > 1) Adults age 18-25 yrs. had significantly increased chances of > > obtaining SVR than most other age groups.> > 2) Pts. >65 had similar SVR to all other age groups. > > 3) Although there were more AEs in the older age groups, the rate of > > SAEs was the same and treatment drop-outs were the same or less than > > the younger age groups. > > 4) Pts. should not be denied anti-viral therapy based upon age alone.> > > > *Poster presents data updated since abstract submission.> > > > > > The Weight-Based Dosing of Peginterferon alfa-2b and Ribavirin (WIN-> > R) study was a prospective, multicenter, community and academic-> > based, open-label, investigator-initiated, US clinical trial that > > evaluated the efficacy and safety of PEG-IFN alfa-2b plus flat-dose > > or weight-based ribavirin in treatment-naive patients with chronic > > hepatitis C.> > - Overall SVR rates were 44% in the weight-based ribavirin arm and > > 41% in the flat-dose ribavirin arm (P = .020).3> > - SVR rates in patients with chronic hepatitis C caused by hepatitis > > C virus (HCV) genotype 1 (G1) were 34% and 29%, respectively (P > > =.004).3> > - Weight-based ribavirin dosing was associated with higher rates of > > dose reduction for anemia but not with higher rates of > > discontinuation.3> >> > > > > > > --------------------------------------------------------------------> Everyone is raving about the all-new beta.>